DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer

DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer Che-Hung Shen, Chi-Che Hsieh, Ting-Wei Li, Chun-Chun Li, Shang-Hung Chen, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4023430/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 27 Sep, 2024 Read the published version in Oncogenesis → Version 1 posted You are reading this latest preprint version Abstract Oxaliplatin is effective against colorectal cancer (CRC), but resistance hampers treatment. We found upregulated Dickkopf-1 (DKK1, a secreted protein) in oxaliplatin-resistant (OR) CRC cell lines and DKK1 levels increased by more than 2-fold in approximately 50% of oxaliplatin-resistant CRC tumors. DKK1 activates AKT via cytoskeleton-associated protein 4 (CKAP4, a DKK1 receptor), modulating oxaliplatin responses in vitro and in vivo . The leucine zipper (LZ) domain of CKAP4 and cysteine-rich domain 1 (CRD1) of secreted DKK1 are crucial for their interaction and AKT signaling. By utilizing the LZ protein, we disrupted DKK1 signaling, enhancing oxaliplatin sensitivity in OR CRC cells and xenograft tumors. This suggests that DKK1 as a chemoresistant factor in CRC via AKT activation. Targeting DKK1 with the LZ protein offers a promising therapeutic strategy for oxaliplatin-resistant CRC with high DKK1 levels. This study sheds light on oxaliplatin resistance mechanisms and proposes an innovative intervention for managing this challenge. Biological sciences/Cancer/Cancer therapy/Cancer therapeutic resistance Biological sciences/Cancer/Gastrointestinal cancer/Colorectal cancer DKK1 CKAP4 oxaliplatin resistance colorectal cancer Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 INTRODUCTION Colorectal cancer (CRC) arises from benign polyps, posing challenges due to rising incidence, high mortality, and drug resistance. Surgical resection is the mainstay treatment, yet for unresectable cases or surgery intolerance, drug or radiation therapies are used pre- or post-surgery to shrink tumors or as adjuvant treatments [ 1 – 3 ]. Oxaliplatin, a third-generation platinum-based compound, induces DNA interstrand crosslinks, forming DNA-Pt adducts that disrupt DNA replication, leading to cell cycle arrest and apoptosis. Despite its efficacy, prolonged or repeated use of oxaliplatin often results in drug resistance, adverse events, tumor relapse, and reduced survival in CRC patients [ 4 – 6 ]. Therefore, comprehending how CRC surpasses oxaliplatin treatments is crucial. This insight will aid in devising innovative therapeutic approaches to enhance the clinical care of patients with oxaliplatin-resistant (OR) CRC. Proposed mechanisms for oxaliplatin resistance include alterations in DNA damage response, changes in cell death and survival pathways, and alters in protein expression [ 7 – 11 ]. Pro-survival pathways such as AKT activation have been implicated in preventing cancer cell death. Notably, increased AKT activity have been observed in OR cancer cells, including hepatoma HepG2 cells [ 12 ], colorectal cancer cells [ 13 – 15 ], and cholangiocarcinoma cells [ 16 ]. Inhibiting the PI3K/AKT pathway has shown efficacy in enhancing oxaliplatin sensitivity in OR HepG2 [ 12 ] and OR CRC HCT116 cells [ 14 ]. These studies collectively highlight the critical role of AKT in fostering oxaliplatin resistance in cancer cells. Dickkopf1 (DKK1), initially identified as an embryonic head inducer, holds significant importance in embryo development [ 17 , 18 ]. This secreted protein contains two cysteine-rich domains: CRD1 and CRD2. The CRD1 domain interacts with the leucine zipper (LZ) domain of cytoskeleton-associated protein 4 (CKAP4) [ 19 ]. The CRD2 domain is required for interaction with low-density lipoprotein receptor-related protein 6 (LRP6), identified as the first DKK1 receptor [ 20 ]. Canonically, DKK1 acts as a tumor suppressor by inhibiting Wnt signaling [ 17 ]. It forms a complex with LRP6 or Kremen receptors, leading to β-catenin degradation and Wnt signaling suppression. However, mutations in Wnt signaling components are common in human cancers. Despite its canonical role, DKK1 is often upregulated in various human cancers. A meta-analysis demonstrated that increased DKK1 expression correlates with shorter progression-free survival, disease-free survival, and time to recurrence in various cancers, including digestive system cancers [ 21 ]. Elevated DKK1 levels in tumor tissues are associated with poor prognosis in rectal cancer, non-small cell lung cancer, and esophageal squamous cell carcinoma [ 22 , 23 ]. Additionally, high serum DKK1 levels are detected in CRC patients with liver metastasis, correlating with poorer overall survival [ 24 ]. It shows that DKK1 promotes the invasive ability of cancer cells in both gain- and loss-of-function studies [ 25 , 26 ]. Recent research highlights the involvement of the DKK1-CKAP4 signal axis in tumor progression via AKT activation [ 19 , 27 , 28 ]. While DKK1’s role in promoting tumor malignant transformation is established, its link to drug resistance development remains underexplored. Therapeutic strategies targeting the DKK1/CKAP4 interaction are in development. Elevated levels of DKK1 are associated with focal bone lesions in multiple myeloma (MM) [ 29 ]. Preclinical studies in mice with human MM showed that the humanized DKK1-neutralizing antibody BHQ880 reduced MM cell numbers [ 30 ]. A phase IB study found that combining BHQ880 with zoledronic acid was tolerated and showed potential clinical activity in MM patients [ 31 ]. Another humanized DKK1-neutralizing antibody, DKN-01, demonstrated tolerability and clinical activity in phase I studies with advanced biliary cancer, non-small cell lung cancer, esophageal cancer, and gastroesophageal junction tumors [ 32 – 34 ]. In a phase II study, DKN-01 combined with tislelizumab and chemotherapy improved overall survival in advanced gastroesophageal adenocarcinoma patients [ 35 ]. Furthermore, anti-CKAP4 monoclonal antibodies effectively blocked the DKK1/CKAP4 interaction, reducing AKT activation, pancreatic cancer cell proliferation, and tumor growth in mouse models [ 36 ]. Overall, these findings suggest that inhibiting DKK1 signaling holds promise as a cancer therapeutic strategy. In our study, we found elevated DKK1 expression in OR CRC cells through protein array analysis. DKK1/CKAP4/AKT signaling activation significantly influences oxaliplatin responses in CRC cell and xenograft tumor models. Knockdown of DKK1 or CKAP4 not only suppresses AKT signaling but also enhances oxaliplatin sensitivity in OR CRC cells. Exposure to DKK1-containing conditional medium stimulates AKT signaling, thus reducing oxaliplatin-induced apoptosis and CRC cell sensitivity to oxaliplatin. Our findings reveal the importance of DKK1's cysteine-rich domain 1 (CRD1) and CKAP4's leucine zipper (LZ) domain in their cell surface interaction. Moreover, the LZ protein effectively disrupts DKK1-CKAP4 interaction, rendering OR CRC cells susceptible to oxaliplatin both in vitro and in vivo xenograft tumors. We suggest that DKK1 promotes chemoresistance in CRC cells by activating AKT signaling. Consequently, targeting DKK1 emerges as a promising therapeutic strategy for CRC patients with oxaliplatin resistance. RESULTS DKK1 is upregulated in oxaliplatin-resistant colorectal cancer cells OR CRC cell lines (LoVo-OR, SW48-OR, and CA01-OR) were created following established protocols [ 7 ]. Utilizing MTS-based assays revealed reduced sensitivity to oxaliplatin compared to parental cells (P) (Fig. 1 A). Further analysis via tumor sphere formation (Supplementary Fig. 1A) and xenograft assays confirmed the robust growth of LoVo-OR cells in the presence of oxaliplatin (Fig. 1 B and Supplementary Fig. 1B). To explore molecular factors influencing oxaliplatin responses, we conducted proteomic analysis comparing LoVo-OR and LoVo-P tumor spheres. Utilizing the Proteome Profiler Human XL Oncology Array, we identified 3 downregulated and 4 upregulated proteins in LoVo-OR spheres, notably FGF2 and DKK1 (Fig. 1 C and Supplementary Fig. 1C). Dysregulation of FGF signaling is associated with aggressive cancer traits, drug resistance, and poor clinical outcomes [ 37 ]. However, analysis from the UALCAN database showed that FGF2 upregulation wasn't significantly linked to colon adenocarcinoma (COAD) tissues, tumor stages, lymph node status, or clinical outcomes (Supplementary Fig. 1D-G). DKK1 is frequently upregulated in various tumors and is associated with poor prognosis in patients [ 25 , 38 , 39 ]. Analysis of the UALCAN database showed a significant increase in DKK1 expression in COAD tissues (P = 0.0019) across different tumor stages and lymph node statuses (Supplementary Fig. 1H-J), suggesting its potential as a diagnostic marker for COAD patients. Although the association between DKK1 mRNA expression and overall survival (OS) in COAD patients was not statistically significant (Supplementary Fig. 1K), we aimed to investigate its role in oxaliplatin resistance in CRC. Western blotting analysis of CRC tumor spheres demonstrated upregulated DKK1 expression OR cell lines (LoVo-OR, SW48-OR, and CA01-OR) compared to their oxaliplatin-sensitive counterparts (P) (Fig. 1 D). As DKK1 is a secreted protein, we examined its levels in the cell culture media. Daily collection of medium samples showed detectable DKK1 protein in both LoVo-P and LoVo-OR cells, with higher levels in LoVo-OR cells (Fig. 1 E). Enzyme-linked immunosorbent assay (ELISA) quantification normalized against cell numbers confirmed more efficient DKK1 secretion in LoVo-OR cells, with a concentration of secreted DKK1 (sDKK1) measured at 0.084 ± 0.023 ng/µl in LoVo-OR cell culture medium on day 3 (Fig. 1 F). Downregulation DKK1/CKAP4/AKT signaling facilitates oxaliplatin resistance in colorectal cancer cells DKK1 is known to bind, cytoskeleton-associated protein 4 (CKAP4, a membrane protein), activating downstream AKT signaling and facilitating cancer cell proliferation and malignant transformation [ 17 , 38 ]. To explore the involvement of DKK1 signaling in oxaliplatin resistance in CRC, we examined AKT activation, finding a positive correlation with increased DKK1 expression in OR CRC tumor spheres (Fig. 1 D). Using RNA interference (RNAi), we reduced DKK1 expression with two independent DKK1-specific shRNAs (#85 and #88). SW48-OR cells expressing DKK1 shRNAs showed decreased DKK1 expression, leading to reduced phospho-AKT levels at Thr308 and Ser473 (Fig. 2 A). DKK1 knockdown inhibited SW48-OR colony formation in soft-agar assays (Fig. 2 B) and significantly reduced the number of SW48-OR tumor spheres in the presence of oxaliplatin (Fig. 2 C). Similar results were observed in LoVo-OR and CA01-OR cells (Supplementary Fig. 2A-D), underscoring DKK1's crucial role in activating AKT and modulating oxaliplatin responses in resistant CRC cells. Subsequently, UALCAN database analysis revealed elevated CKAP4 expression in COAD tissues (P = 0.0016), significant across tumor stages and lymph node status (Supplementary Fig. 2E-G). Although the association between CKAP4 mRNA expression and overall survival (OS) in COAD patients wasn't statistically significant (Supplementary Fig. 2H), we investigated CKAP4's role in mediating DKK1-stimulated AKT signaling. SW48-OR cells expressing CKAP4 shRNAs exhibited decreased CKAP4 expression, reduced AKT activity, and impaired colony and tumor sphere formation compared to controls with scrambled shRNAs (Fig. 2 D-F). Similar effects were seen in LoVo-OR and CA01-OR cells (Supplementary Fig. 2I-L). In conclusion, our findings suggest that DKK1/CKAP4/AKT signaling axis is upregulated in oxaliplatin-resistant CRC cells and plays a crucial role in promoting cell growth in the presence of oxaliplatin. Secreted DKK1-mediated activation of AKT signaling via CKAP4 in colorectal cancer cells The DKK1/CKAP4/AKT signaling axis's impact on cancer biology has been previously demonstrated by manipulating cellular DKK1 expression levels [ 19 , 38 ]. We aimed to address the function of secreted DKK1 (sDKK1) in CRC cells. sDKK1-containing conditioned media (CM) was obtained from 293 cells expressing 3xFlag-tagged DKK1 (DKK1-3xF, Supplementary Fig. 3A) after a 3-day serum-free medium incubation. Levels of DKK1-3xF in CM were assessed via western blotting (Supplementary Fig. 3B) and ELISA. Time-course CM treatment of SW48 cells revealed significant AKT activation at the 30-minute mark with DKK1-3xF, contrasting with negligible effects observed with mock CM (Fig. 3 A). To assess sDKK1’s interaction with the CKAP4 receptor, we employed a truncated form of DKK1 lacking CRD1 (DKK1ΔCRD1-3xF; Supplementary Fig. 3A), responsible for CKAP4 interaction [ 40 ]. CM containing DKK1ΔCRD1-3xF (ΔCRD1-3xF) was collected and leveled (Supplementary Fig. 3B), revealing reduced DKK1-induced AKT phosphorylation in SW48 cells (Fig. 3 A), similarly observed in CA01 cells (Supplementary Fig. 3C). Subsequently, we explored CKAP4’s role in mediating sDKK1-induced AKT signaling. SW48 cells expressing shRNAs against CKAP4 treated with DKK1-3xF-containing CM showed partially attenuated DKK1-3xF-induced phospho-AKT levels (Fig. 3 B), suggesting CKAP4’s involvement in mediating sDKK1-activated AKT. Additionally, to visualize sDKK1's interaction with CKAP4 on the plasma membrane, we generated a DKK1-GFP fusion protein, where GFP was tagged at DKK1’s C-terminus. The signal peptide (SP) [ 41 ] derived from DKK1 was fused to the N-terminus of GFP (SP-GFP) for GFP secretion guidance, serving as a control (Supplementary Fig. 3A). CM collected from 293 cells expressing SP-GFP (SP), DKK1-GFP (DKK1), or DKK1ΔCRD1-GFP (ΔCRD1) was analyzed and leveled (Supplementary Fig. 3D). Flow cytometry analysis of SW48 cells incubated with CM revealed a significant decrease in GFP + cells with ΔCRD1 CM compared to DKK1 CM (Fig. 3 C and Supplementary Fig. 3E). Plasma membrane isolation assays confirmed DKK1 presence in the plasma membrane fraction, with reduced levels for ΔCRD1, supporting sDKK1’s binding to the cell plasma membrane, attenuated by CRD1 truncation (Fig. 3 D). To validate CKAP4’s role in sDKK1-cell interactions, flow cytometry analysis of SW48 cells expressing shRNAs against CKAP4 incubated with DKK1 CM revealed reduced GFP + cells (Fig. 3 E and Supplementary Fig. 3F). Immunocytochemistry (ICC) analysis further confirmed sDKK1's association with the plasma membrane and CKAP4, with colocalization observed and reduced by CRD1 truncation (Fig. 3 F). These findings support CRD1’s critical role in sDKK1 interaction with CKAP4 on the cell surface to activate AKT signaling. sDKK1 modulates oxaliplatin responses in CRC cells Next, we investigated the impact of sDKK1 on oxaliplatin responses in CRC cells via the CKAP4/AKT pathway. CM containing sDKK1 was obtained from 293 cells expressing DKK1-3xF, DKK1ΔCRD1-3xF (ΔCRD1-3xF), or an empty vector (Mock). SW48 cells treated with 0.1 µM oxaliplatin for 24 hours, followed by a 30-minute CM incubation. Western blotting showed increased phospho-AKT levels with DKK1-3xF CM, partially restoring oxaliplatin-inhibited AKT phosphorylation, weakened by CRD1 truncation (Fig. 4 A). MTS assays indicated no significant effect on cell proliferation, but DKK1-3xF CM partially rescued oxaliplatin-inhibited cell growth (Fig. 4 B). Similar results were observed in CA01 cells (Fig. 4 C and D). Apoptosis assays in SW48 cells showed DKK1-3xF CM minimized oxaliplatin-induced early apoptosis compared to mock or ΔCRD1-3xF CM (Fig. 4 E and Supplementary Fig. 4A). Long-term focus formation assays in SW48 cells stably expressing DKK1-3xF and ΔCRD1-3xF indicated DKK1 expression partially rescued cells from oxaliplatin treatment (Fig. 4 F and Supplementary Fig. 4B). Anchorage-independent cell growth assays in SW48 cells demonstrated DKK1 expression partially restored oxaliplatin-suppressed sphere growth, whereas ΔCRD1 did not (Fig. 4 G and Supplementary Fig. 4C). These findings collectively suggest sDKK1 contributes to modulating oxaliplatin responses through the CKAP4/AKT pathway. DKK1 sustains CRC tumor growth in the presence of oxaliplatin In a study on CRC's oxaliplatin resistance, CA01 cells expressing SP-GFP (SP) or DKK1-GFP (DKK1) were xenografted into mice. Mice received mock or oxaliplatin injections (5 mg/kg) weekly for 3 weeks. DKK1-GFP expression had no significant effect on tumor volume. However, oxaliplatin notably reduced tumor volume in SP-GFP tumors, whereas DKK1-GFP tumors-maintained growth (Fig. 5 A and B). By treatment end, SP-GFP tumors decreased while DKK1-GFP tumors increased in size (Fig. 5 C). Immunohistochemistry (IHC) analysis revealed a decrease in Ki67 + cells to 33.7 ± 8.5% and an increase in TUNEL + cells to 9.4 ± 1.5% in SP-GFP tumors, whereas these responses were attenuated in DKK1-GFP tumors (Fig. 5 D and E, and Supplementary Fig. 5A and B). To confirm DKK1-GFP secretion in tumor-bearing mice, blood plasma underwent immunoprecipitation with anti-GFP antibodies and protein A/G beads. Western blotting confirmed GFP fusion protein presence, indicating SP-GFP and DKK1-GFP secretion from tumors into the blood (Supplementary Fig. 5C). Findings from SW48 cells expressing DKK1-3xF (WT), DKK1ΔCRD1-3xF (ΔCRD1), or empty vector (Vec) mirrored those in CA01 xenograft tumors. DKK1 or ΔCRD1 expression didn't significantly enhance SW48 xenograft growth. Oxaliplatin notably reduced tumor volume in ΔCRD1 or Vec tumors, while DKK1-expressing tumors remained stable (Supplementary Fig. 5D and E). By treatment end, ΔCRD1 and Vec tumors decreased in size, while DKK1 tumors increased (Supplementary Fig. 5F). Animal body weights remained consistent throughout treatment (Supplementary Fig. 5G). These findings support elevated DKK1 sustaining CRC tumor growth in oxaliplatin presence, indicating its key role in oxaliplatin resistance in colorectal cancer. To associate DKK1 expression with oxaliplatin resistance onset in CRC patients, we conducted IHC on 12 pairs of pre-treatment and post-relapse tumor samples from oxaliplatin-treated patients (Fig. 5 F). DKK1 expression was quantified using the IHC H-score. Statistical analysis revealed a significant difference in DKK1 expression between pre-treatment and post-relapse CRC samples (p = 0.0197, Supplementary Fig. 5H). Normalizing DKK1 H-scores from 12 post-relapse samples against their pre-treatment counterparts yielded fold changes in DKK1 expression (Fig. 5 G). Remarkably, increased DKK1 H-scores (fold change > 1.0) were found in 9 OR CRCs, constituting 75% of the total 12 CRCs. Among these, 6 OR CRCs (50% of the total 12 CRCs) exhibited over a 2-fold increase in DKK1 H-score (Fig. 5 G). These results strongly suggest a positive association between DKK1 expression and oxaliplatin resistance development in CRC. LZ protein suppresses oxaliplatin-resistant CRC cell growth Our findings suggest that the crucial role of the DKK1/CKAP4 interaction in regulating oxaliplatin responses in CRC cell lines, indicating a potential therapeutic strategy for suppressing OR CRC cell growth. Given the reported requirement for the LZ domain in CKAP4 and the CRD1 in DKK1 for their interaction [ 19 , 40 ], we investigated the disruptive potential of an LZ domain-containing protein. We cloned a one-hundred-amino-acid region overlapping the defined LZ domain (aa 468–503) of CKAP4 [ 38 ], generating a secreted form of the SP-LZ-mCherry fusion protein (LZ protein) (Supplementary Fig. 6A). CM containing LZ protein or SP-mCherry was collected, confirmed, and normalized for consistency (Supplementary Fig. 6B). To assess the interaction of the LZ protein with sDKK1 via CRD1, immunoprecipitation assays were performed using anti-DsRed antibodies with CMs containing DKK1-GFP and LZ protein. The results revealed GFP fusion proteins in the anti-DsRed immunoprecipitation complex in DKK1-GFP CM, with diminished levels in DKK1ΔCRD1-GFP CM (Supplementary Fig. 6C), suggesting that the CRD1 mainly facilitates the interaction between the LZ protein and sDKK1. Further validation of the specificity of the LZ protein/sDKK1 interaction was achieved, demonstrating the specific interaction of the LZ protein with both exogenously expressed DKK1-GFP and endogenous sDKK1 proteins (Fig. 6 A and B). To assess the impact of the LZ protein on the binding of sDKK1 to CKAP4 on the cell surface, flow cytometry and ICC analyses were performed using SW48 cells incubated with DKK1-GFP + SP-mCherry CM or DKK1-GFP + LZ protein CM for 30 minutes. The percentage of GFP + cells (Fig. 6 C and Supplementary Fig. 6D) and the association of sDKK1-GFP with the cell surface (Fig. 6 D) were reduced by the presence of LZ protein CM, contrasting with SP-mCherry. These results suggest that the LZ protein functions by sequestering sDKK1, thereby interfering with the binding of sDKK1 to CKAP4 on the cell surface. We then evaluated the LZ protein's therapeutic potential in inhibiting OR CRC growth. Long-term focus formation assays demonstrated significantly inhibited colony formation in LoVo-OR cells when exposed to LZ protein CM compared to SP-mCherry (Fig. 6 E). To validate these findings, LoVo-OR cells were xenografted into mice, divided into SP and LZ groups, and administrated SP-mCherry CM and LZ protein CM three times per week for 3 weeks. After CM withdrawal, tumor growth was monitored for an additional 3 weeks with continuous oxaliplatin administration (Supplementary Fig. 6E). Notably, LoVo-OR tumor growth was significantly suppressed in the LZ group compared to the SP group, and this effect persisted for up to 3 weeks after discontinuing LZ protein CM administration (Fig. 6 F and Supplementary Fig. 6F). Importantly, there were no discernible effects on the mice’s body weight (Supplementary Fig. 6G), suggesting the safety of CM administration. Additionally, IHC analysis of tumor samples revealed a reduced percentage of actively proliferating tumor cells (96.9 ± 0.9% in SP, and 59.4 ± 6.5% in LZ) and an increased percentage of apoptotic cells (0.8 ± 0.4 in SP, and 12.5 ± 4.8% in LZ) in the LZ group (Fig. 6 G, and Supplementary Fig. 6H and I). These findings collectively support the LZ protein's inhibitory effect on oxaliplatin-resistant CRC growth, suggesting a promising therapeutic strategy for CRC characterized by elevated DKK1 levels. DISCUSSION Our study reveals a clear link between DKK1 expression and oxaliplatin resistance in colorectal cancer. DKK1 secretion is notably higher in OR CRC cells compared to parental cells. Clinically, DKK1 expression is significantly elevated in post-relapse tumors from patients on oxaliplatin-based chemotherapy, suggesting its role in resistance development in CRC. Mechanistically, we demonstrated that secreted DKK1 (sDKK1) activates AKT by binding CKAP4 on the cell membrane. This DKK1 signaling shields CRC cells from oxaliplatin-induced cytotoxicity, causing oxaliplatin resistance in vitro and in vivo. Importantly, blocking the DKK1/CKAP4 interaction with the LZ protein heightened OR CRC cells' sensitivity to oxaliplatin and inhibited OR CRC xenograft tumor growth. In summary, our findings highlight two main points: 1) DKK1 signaling is pivotal in regulating oxaliplatin responses in CRC, and 2) inhibiting the DKK1/CKAP4 interaction using the LZ domain could be a promising therapy for oxaliplatin-resistant CRC. AKT activation is intricately regulated by diverse upstream pathways, notably phosphatidylinositol-3-kinase (PI3K), which regulates fundamental cellular processes like apoptosis, proliferation, and differentiation. This pathway, notorious for driving malignant transformation, is implicated in key cancer features. Moreover, AKT activation is strongly linked to drug resistance in various cancers[ 42 , 43 ], including cisplatin-resistant lung cancer [ 44 ], acquired resistance to standard therapies breast cancer [ 45 ], and BRAF inhibitor-resistant melanoma [ 46 ]. Our study revealed that sDKK1's role in stimulating AKT activation in oxaliplatin resistance. Exploring DKK1 signaling in other AKT-driven drug-resistant cancers and assessing the LZ protein's effects could be promising future research directions. Clinical studies link higher DKK1 levels with shorter recurrence times and poorer prognosis in patients[ 21 – 23 ]. Elevated DKK1 is seen in CRC patients with liver metastasis, correlating with reduced overall survival[ 24 ]. Both gain- and loss-of-function studies show DKK1’s role in tumor progression and malignant transformation through the DKK1/CKAP4/AKT signaling [ 19 , 27 , 28 ]. In our study, while DKK1 minimally affects CRC tumor growth, the DKK1/CKAP4/AKT axis significantly influences oxaliplatin responses, including cell proliferation, colony formation, anchorage-independent cell growth, apoptosis, and xenograft tumor growth in different CRC cell lines. It's proposed that DKK1's CRD1 and CKAP4's LZ domain are crucial for their interaction, supported by immunoprecipitation-western blot (IP-WB) assays using cell lysates from cells expressing variants of DKK1 or CKAP4 [ 19 ]. To explore their cell surface interaction, we utilized GFP-tagged DKK1 in conditioned medium to visualize sDKK1 binding to the cell membrane. Our findings highlight the essential role of CRD1 in sDKK1's association with CKAP4 on the cell surface, as evidenced by reduced AKT activity, membrane association, and modulation of oxaliplatin responses upon incubation with CRD1-truncated DKK1. This underscores the therapeutic potential of targeting the DKK1/CKAP4 interaction in OR CRCs. In our strategy, rather than creating DKK1-neutralizing antibodies, we designed an SP-LZ-mCherry fusion protein, utilizing the signal peptide (SP) to guide LZ-mCherry secretion. These secreted LZ proteins interact efficiently with DKK1, disrupting the DKK1/CKAP4 interaction on the cell membrane. This approach effectively inhibits colony formation and xenograft tumor growth in OR CRC cells, highlighting the LZ protein's therapeutic promise for OR CRC. Future research will assess the LZ protein's anti-tumor efficacy in DKK1-overexpressing cancers. Notably, DKK1's association with a suppressive tumor immune microenvironment (TIME) and its potential as an immunotherapeutic target are significant[ 47 , 48 ]. Therefore, investigating the LZ protein's impact on DKK1-mediated TIME modulation is crucial. Our study presents a novel approach to dampen DKK1 signaling via the LZ protein, offering a convenient method for generating LZ fusion proteins through SP-directed protein secretion. Our study not only unveiled a positive association between the expression of DKK1 and the development of oxaliplatin resistance in colorectal cancer (CRC) but also elucidated the molecular mechanism through which the DKK1/CKAP4 interaction modulates oxaliplatin responses. Furthermore, our results strongly indicate that attenuating the DKK1/CKAP4/AKT signaling axis using the LZ protein effectively suppressed oxaliplatin-resistant (OR) CRC cell growth both in vitro and in vivo (Supplementary Fig. 6J). This finding holds promise as a potential therapeutic strategy for the treatment of OR CRC. MATERIALS AND METHODS Patient samples and establishment of a colorectal cancer cell line Patients provided signed informed consent prior to their inclusion in this study, which was approved by the institutional review board at the National Cheng Kung University Hospital (B-BR-106-068, NCKUH, Tainan, Taiwan). Patients with CRC were enrolled and received oxaliplatin-based chemotherapy. The pre-treatment tumor biopsies were performed, and pair-matched post-relapse tumor biopsies were collected at the time of progression. No statistical method was used to predetermine the sample size. No samples were excluded. The formalin-fixed tissue was analyzed to confirm the presence of viable tumor by hematoxylin and eosin (H&E) staining. To generate a primary CRC cell line, CA01, the procedures were performed as previously described [ 49 ]. Briefly, a tumor section was excised from a 63-year-old Taiwanese woman who underwent surgical operations at NCKU in 2020 (0140140-2). The sample was mechanically fragmented and enzymatically digested. Cells were collected and cultured in DMEM/F-12 medium (Gibco, Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 100 U/ml of penicillin–streptomycin (Gibco) for further experiments. In vivo xenograft tumor growth studies Mice were maintained in accordance with facility guidelines on animal welfare and with protocols approved by the Institutional Animal Care and Usage Committee (IACUC) of the National Cheng Kung University. Four- to 6-week-old female NOD/SCID mice (NCKU, Tainan, Taiwan) were housed in a specific pathogen-free environment in the animal facility of NCKU. For oxaliplatin sensitivity assays, 1 × 10 7 LoVo-P or LoVo-OR cells were mixed with Matrigel (1:1, BD Biosciences, Franklin Lakes, NJ, USA) and subcutaneously inoculated into the flanks of the mice. LoVo-OR tumor-bearing mice (n = 3) were administered oxaliplatin (5 mg/kg) once per week for 6 weeks by intraperitoneal injection. The LoVo-P tumor-bearing mice were grouped into mock (n = 3) and OXA (n = 3) groups when tumor size reached 100 mm 3 . The mock group was administered PBS, and the OXA group was given 5 mg/kg oxaliplatin once per week for 6 weeks by intraperitoneal injection. To evaluate the effects of DKK1 on oxaliplatin sensitivity, 2 x 10 6 CA01 cells stably expressing SP-GFP or DKK1-GFP were grown as xenograft tumors. When tumor size reached 100 mm 3 , mice were randomly assigned to two groups: mock (n = 6) and OXA (n = 6). The mock group was administered PBS, and the OXA group was administered 5 mg/kg oxaliplatin once per week for 3 weeks by intraperitoneal injection. In addition, 2 x 10 6 SW48 cells stably expressing DKK1-3xF, DKK1ΔCRD1-3xF, or carrying an empty vector were grown as xenograft tumors. The tumor-bearing mice were randomly assigned to two groups: mock (n = 6) and OXA (n = 6). The mock group was administered PBS, and the OXA group was administered 5 mg/kg oxaliplatin once per week for 3 weeks by intraperitoneal injection. To address the impact of the LZ protein on suppressing oxaliplatin-resistant tumor growth, 1 × 10 7 LoVo-OR cells were subcutaneously inoculated into the flanks of the mice. The mice were administered 5 mg/kg oxaliplatin once per week. When the tumor size reached 100 mm 3 , the tumor-bearing mice were randomly assigned to two groups: SP (n = 6) and LZ (n = 6). The SP group was intraperitoneally injected with SP-mCherry containing CM and the LZ group was administered SP-LZ-mCherry containing CM three times per week for 3 weeks. After CM withdrawal, the tumor growth was monitored for an additional 3 weeks. Oxaliplatin was administered throughout the courses. The tumor-bearing mice were randomly grouped using Research Randomizer at http://www.randomizer.org . The sample size was not statistically determined. Tumors and body weight were monitored daily. Tumor size was calculated using the following formula: volume = [length × (width)²] / 2. The relative tumor volume was determined by dividing the volume of oxaliplatin-treated tumors by that of mock-treated tumors. When the tumor size reached 1000 mm³, the mice were humanely euthanized. The investigators were not blinded to group allocation or outcome assessment, and no animals were excluded from the experiments. Statistics Statistical analyses were performed using Prism 8 (GraphPad Software, New York City, NY, USA). The in vitro experiments were performed in biological triplicate each time and independently repeated at least 3 times. Data are presented as the mean ± SEM and the number (n) of samples used was as indicated. An unpaired two-tailed Student’s t-test was used to compare differences between the control and experimental groups, unless otherwise indicated. For all statistical analyses, differences were labeled as *, P < 0.05; **, P < 0.01; *** P < 0.001; ****; n.s. = not significant. P values < 0.05 was considered statistically significant. Declarations DATA AVAILABILITY All materials are available upon reasonable request to [email protected] . COMPETING INTERESTS The authors have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript. FUNDING This research was supported by the National Health Research Institutes, Taiwan (CA-112-PP-23 to CHS), National Science and Technology Council, Taiwan (MOST 110-2314-B-400-019-MY3 to CHS), and Taipei Veterans General Hospital (V112C-137 to NJC). AUTHOR CONTRIBUTIONS CCH: Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing-review & editing. TWL: Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing-review & editing. CCL: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing-review & editing. SHC: Formal analysis, Investigation, Resources, Writing-review & editing. YLW: Data curation, Formal analysis, Methodology, Writing-review & editing. NJC: Conceptualization, Formal analysis, Funding acquisition, Investigation, Resources, Writing-review & editing. CHS: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing-original draft preparation. ACKNOWLEDGMENTS We thank the support from the Human Biobank, Research Center of Clinical Medicine and the Cancer Data Bank of National Cheng Kung University Hospital, Taiwan. We thank the technical services provided by the Bio-image Core Facility of the National Core Facility Program for Biotechnology, Ministry of Science and Technology, Taiwan. References Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG et al . Colorectal cancer. Nature Reviews Disease Primers 2015; 1: 15065. Brown KGM, Solomon MJ, Mahon K, O'Shannassy S. Management of colorectal cancer. BMJ 2019; 366: l4561. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group EGW. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 Suppl 3: iii1-9. Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C et al . Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. British Journal of Cancer 2004; 91: 1931-1946. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cellular and Molecular Life Sciences CMLS 2002; 59: 1914-1927. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist 2004; 9: 8-12. Hsieh CC, Hsu SH, Lin CY, Liaw HJ, Li TW, Jiang KY et al . CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer. Br J Cancer 2022; 127: 1615-1628. Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag 2009; 5: 229-238. Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol 2014; 20: 9775-9827. Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013; 6: 988-1038. Martinez-Balibrea E, Martinez-Cardus A, Gines A, Ruiz de Porras V, Moutinho C, Layos L et al . Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance. Mol Cancer Ther 2015; 14: 1767-1776. Xu R, Zhang Y, Li A, Ma Y, Cai W, Song L et al . LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1alpha pathway. Mol Med Rep 2021; 24. Park SY, Chung YS, Park SY, Kim SH. Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer. Biomedicines 2022; 10. Wei W, Ma XD, Jiang GM, Shi B, Zhong W, Sun CL et al . The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1. Oncol Res 2020; 28: 423-438. Yu T, An Q, Cao X-L, Yang H, Cui J, Li Z-J et al . GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway. Life Sciences 2020; 260: 118294. Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S, Tungpradubkul S. Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int 2009; 9: 3. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006; 25: 7469-7481. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998; 391: 357-362. Kimura H, Fumoto K, Shojima K, Nojima S, Osugi Y, Tomihara H et al . CKAP4 is a Dickkopf1 receptor and is involved in tumor progression. J Clin Invest 2016; 126: 2689-2705. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A et al . LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001; 411: 321-325. Huang J, Lu T, Kuang W. Prognostic role of dickkopf-1 in patients with cancer. Medicine (Baltimore) 2020; 99: e20388. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M et al . Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007; 67: 2517-2525. Kemik O, Kemik AS, Sumer A, Begenik H, Purisa S, Tuzun S et al . Relationship Between Clinicopathologic Variables and Serum and Tissue Levels of Dickkopf-1 in Patients With Rectal Cancer. Journal of Investigative Medicine 2011; 59: 947. Sui Q, Zheng J, Liu D, Peng J, Ou Q, Tang J et al . Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study. BMC Cancer 2019; 19: 1210. Kagey MH, He X. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. Br J Pharmacol 2017; 174: 4637-4650. Chen L, Li M, Li Q, Wang C-j, Xie S-q. DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway. Molecular Cancer 2013; 12: 157. Iguchi K, Sada R, Matsumoto S, Kimura H, Zen Y, Akita M et al . DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness. Cancer Sci 2023; 114: 2063-2077. Shinno N, Kimura H, Sada R, Takiguchi S, Mori M, Fumoto K et al . Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug. Oncogene 2018; 37: 3471-3484. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al . The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA et al . Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371-379. Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R et al . A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 2014; 167: 366-375. Edenfield WJ, Richards DA, Vukelja SJ, Weiss GJ, Sirard CA, Landau SB et al . A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer. Journal of Clinical Oncology 2014; 32: 8068-8068. Eads J, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana AA et al . Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC). Annals of Oncology 2016; 27. Ryan DP, Murphy J, Mahalingam D, Strickler J, Stein S, Sirard C et al . PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). Annals of Oncology 2016; 27. Klempner SJ, Sirard C, Chao J, Chiu V, Mahalingam D, Uronis H et al . 1384P DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial. Annals of Oncology 2021; 32: S1048-S1049. Kimura H, Yamamoto H, Harada T, Fumoto K, Osugi Y, Sada R et al . CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy. Clin Cancer Res 2019; 25: 1936-1947. Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM et al . Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget 2016; 7: 44735-44762. Kikuchi A, Fumoto K, Kimura H. The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy. Br J Pharmacol 2017; 174: 4651-4665. Kikuchi A, Matsumoto S, Sada R. Dickkopf signaling, beyond Wnt-mediated biology. Semin Cell Dev Biol 2022; 125: 55-65. Bhavanasi D, Speer KF, Klein PS. CKAP4 is identified as a receptor for Dickkopf in cancer cells. J Clin Invest 2016; 126: 2419-2421. Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP et al . Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 1999; 274: 19465-19472. Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016; 7: 352-369. Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z et al . PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 2020; 11: 797. Zhang Y, Bao C, Mu Q, Chen J, Wang J, Mi Y et al . Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells. Neoplasma 2016; 63: 362-370. Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Front Pharmacol 2021; 12: 628690. Kozar I, Margue C, Rothengatter S, Haan C, Kreis S. Many ways to resistance: How melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer 2019; 1871: 313-322. Betella I, Turbitt WJ, Szul T, Wu B, Martinez A, Katre A et al . Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer. Gynecol Oncol 2020; 157: 765-774. Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X et al . DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. Cancer Immunol Res 2022; 10: 1506-1524. Hsieh CC, Su YC, Jiang KY, Ito T, Li TW, Kaku-Ito Y et al . TRPM1 promotes tumor progression in acral melanoma by activating the Ca(2+)/CaMKIIdelta/AKT pathway. J Adv Res 2023; 43: 45-57. Additional Declarations There is NO conflict of interest to disclose. Supplementary Files SupOncogenesubmit0301.pdf Cite Share Download PDF Status: Published Journal Publication published 27 Sep, 2024 Read the published version in Oncogenesis → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4023430","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":277058081,"identity":"a6147aee-0940-4302-97ee-0f7926f58286","order_by":0,"name":"Che-Hung Shen","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAw0lEQVRIiWNgGAWjYDACCQY2IGnDYMDA2MAAZhOpJQ2hhYdILYeBWkCAGC38s9ufPfi443yeufThBoYPZYcZ7CUSCFhy54y54cwzt4st+xIbGGecO8zAQ0iLgUQOmzRv2+3EDWcYG5h524BapAlqSX8m/bftHETLX+K0JJhJM7YdgGhhJEaLxI0cM8netmSwloM959J5eO4/wK+Ff0b6M4mfbXZALewPH/wos5Zj7zmAXwsKAKklHJOjYBSMglEwCggDAAADQk1+OMVeAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0002-1309-6190","institution":"National Health Research Institutes","correspondingAuthor":true,"prefix":"","firstName":"Che-Hung","middleName":"","lastName":"Shen","suffix":""},{"id":277058082,"identity":"3b7f321f-8fed-447a-b121-b7c30a1b1a72","order_by":1,"name":"Chi-Che Hsieh","email":"","orcid":"","institution":"National Health Research Institutes","correspondingAuthor":false,"prefix":"","firstName":"Chi-Che","middleName":"","lastName":"Hsieh","suffix":""},{"id":277058083,"identity":"5908a3dd-61ed-4338-8239-409c4d90a4b9","order_by":2,"name":"Ting-Wei Li","email":"","orcid":"","institution":"National Health Research Institutes","correspondingAuthor":false,"prefix":"","firstName":"Ting-Wei","middleName":"","lastName":"Li","suffix":""},{"id":277058084,"identity":"82defb62-c50f-4daa-963b-dc15a10ca481","order_by":3,"name":"Chun-Chun Li","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Chun-Chun","middleName":"","lastName":"Li","suffix":""},{"id":277058085,"identity":"80e88525-8a10-4d73-839c-209143d70d4d","order_by":4,"name":"Shang-Hung Chen","email":"","orcid":"","institution":"National Health Research Institutes","correspondingAuthor":false,"prefix":"","firstName":"Shang-Hung","middleName":"","lastName":"Chen","suffix":""},{"id":277058086,"identity":"9fe38d7a-8248-4fa6-8c88-fa458b2de556","order_by":5,"name":"You-Lin Wei","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"You-Lin","middleName":"","lastName":"Wei","suffix":""},{"id":277058087,"identity":"4ea29494-e384-4061-8438-af6131925581","order_by":6,"name":"Nai-Jung Chiang","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Nai-Jung","middleName":"","lastName":"Chiang","suffix":""}],"badges":[],"createdAt":"2024-03-07 07:55:11","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4023430/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4023430/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41389-024-00537-y","type":"published","date":"2024-09-27T04:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":54412519,"identity":"baecc57b-9dc2-45d8-b8f3-d7862017c540","added_by":"auto","created_at":"2024-04-10 05:56:20","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":2790200,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eExpression of DKK1 is upregulated in OR CRC cells. \u003c/strong\u003e(A) Viability of LoVo-OR, SW48-OR, CA01-OR, cells and their parental oxaliplatin-sensitive (P) counterparts after treatment with varying concentrations of oxaliplatin for 3 days. Data are mean ± SEM. * P \u0026lt; 0.05, ** P \u0026lt; 0.01, *** P \u0026lt; 0.001. (n = 3). (B) Growth curves of xenograft tumors derived from LoVo-P and LoVo-OR cells. Mice bearing LoVo-P tumors were treated with mock (n = 3), or administered 5 mg/kg oxaliplatin once per week (n = 3). Mice bearing LoVo-OR tumors were treated with 5 mg/kg oxaliplatin once per week (n = 3). Data are mean ± SEM. *P \u0026lt; 0.05, n.s. = not significant. (C) The relative expression level of proteins between LoVo-P and LoVo-OR cells. Cell lysates from LoVo-P and LoVo-OR cells were prepared and analyzed by a proteome profiler human XL oncology array. Protein spots with different expression levels was quantified (n = 2). (D) Representative western blots of a panel of CRC cell lines. (E) Representative western blots of DKK1 in CM collected from LoVo-P and LoVo-OR at different time points. (F) Quantification of DKK1 in the CM collected from LoVo-P and LoVo-OR at different time points. Data are mean ± SEM. * P \u0026lt; 0.05, ** P \u0026lt; 0.01, *** P \u0026lt; 0.001. (n = 3).\u003c/p\u003e","description":"","filename":"Fig11.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4023430/v1/44f05390180a2a196fb2d86b.jpg"},{"id":54412521,"identity":"8445361d-0e34-42b3-a8a4-4f5c89ae4874","added_by":"auto","created_at":"2024-04-10 05:56:20","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":4072391,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eKnockdown of DKK1 and CKAP4 inhibits AKT activity and cell growth in OR CRC cells.\u003c/strong\u003e (A)Representative western blots of SW48-OR cells stably expressing either a scrambled shRNA or shRNAs specific for DKK1 (left) and quantification (right). β -Actin served as a loading control. * P \u0026lt; 0.05, **P \u0026lt; 0.01. Data are mean ± SEM. (n = 3). (B) Representative images of soft agar colony formation assays for DKK1 knockdown experiments (top) and quantification of colony number (bottom). * P \u0026lt; 0.05, ** P \u0026lt; 0.01. Data are mean ± SEM. (n = 3). (C) Representative images of tumor sphere formation assays for DKK1 knockdown experiments (top) and quantification of tumor sphere number (bottom). *** P \u0026lt; 0.001. Data are mean ± SEM. (n = 3). (D) Representative western blots of SW48-OR cells stably expressing either a scrambled shRNA or shRNAs specific for CKAP4 (left) and quantification (right). β -Actin served as a loading control. * P \u0026lt; 0.05, **P \u0026lt; 0.01, ***P \u0026lt; 0.001. Data are mean ± SEM. (n = 3). (E) Representative images of soft agar colony formation assays for CKAP4 knockdown experiments (top) and quantification of colony number (bottom). * P \u0026lt; 0.05. Data are mean ± SEM. (n = 3). (F) Representative images of tumor sphere formation assays for CKAP4 knockdown experiments (top) and quantification of tumor sphere number (bottom). * P \u0026lt; 0.05, ** P \u0026lt; 0.01. Data are mean ± SEM. (n = 3).\u003c/p\u003e","description":"","filename":"Fig21.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4023430/v1/1beadad896d23f8ac51bee5e.jpg"},{"id":54412520,"identity":"c67c6c33-8fc7-442e-aea7-5123abc44596","added_by":"auto","created_at":"2024-04-10 05:56:20","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":6097787,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eA secreted form of DKK1 promotes AKT activation via CKAP4 engagement in CRC cells.\u003c/strong\u003e (A) Representative western blots of the CM treatment experiments on SW48 cells (top) and quantification analysis (bottom). β -Actin served as a loading control. * P \u0026lt; 0.05. n.s. = not significant. Data are mean ± SEM. (n = 3). (B) Representative western blots of the CM treatment experiments on SW48 cells expressing CKAP4 shRNAs or carrying a scrambled control (left) and quantification analysis (right). β -Actin served as a loading control. * P \u0026lt; 0.05, ** P \u0026lt; 0.01. Data are mean ± SEM. (n = 3). (C) Percentage of GFP\u003csup\u003e+\u003c/sup\u003e cells in the CM treatment experiments on SW48 cells. ***P \u0026lt; 0.001, **** P \u0026lt;0.0001. Data are mean ± SEM. (n = 3). (D) Representative western blots of membrane protein isolation and cell fractionation experiments of the CM treatment experiments on SW48 cells (n = 3). Arrows indicate non-specific bands. (E) Percentage of GFP+ cells in CM treatment experiments on SW48 cells expressing CKAP4 shRNAs or a scrambled control. * P \u0026lt; 0.05. Data are mean ± SEM. (n = 3). (F) Representative images of the CM treatment experiments on SW48 cells, as determined by immunocytochemistry and confocal scanning laser microscopy. Scale bar: 20 μm.\u003c/p\u003e","description":"","filename":"Fig31.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4023430/v1/ee2405a06e8da3ba8af531f7.jpg"},{"id":54412881,"identity":"ed25d216-0e07-4f85-a8b1-e24eb921781d","added_by":"auto","created_at":"2024-04-10 06:04:21","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":3863308,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003esDKK1 modulates oxaliplatin responses in CRC cells.\u003c/strong\u003e (A) Representative western blots of the CM treatment experiments on SW48 cells in response to oxaliplatin (top) and quantification analysis (bottom). β-Actin served as a loading control. * P \u0026lt; 0.05, ** P \u0026lt; 0.01, n.s. = not significant. Data are mean ± SEM (n = 3). (B) Cell growth curves of the CM treatment experiments on SW48 in response to oxaliplatin, as determined by MTS assays. ** P \u0026lt; 0.01, **** P \u0026lt;0.0001, n.s. = not significant. Data are mean ± SEM (n = 3). (C) Representative western blots of the CM treatment experiments on CA01 cells in response to oxaliplatin (top) and quantification analysis (bottom). β-Actin served as a loading control. * P \u0026lt; 0.05, ** P \u0026lt; 0.01, n.s. = not significant. Data are mean ± SEM (n = 3). (D) Cell growth curves of the CM treatment experiments on CA01 in response to oxaliplatin, as determined by MTS assays. * P \u0026lt; 0.05, ** P \u0026lt; 0.01, n.s. = not significant. Data are mean ± SEM (n = 3). (E) Apoptosis analysis was performed in CM treatment experiments on SW48 cells in response to oxaliplatin. ** P \u0026lt; 0.01, *** P \u0026lt; 0.001. n.s. = not significant. Data are mean ± SEM (n = 3). (F) Quantification analysis of clonogenic growth assays for SW48 cells stably expressing DKK1-3xF (WT) and DKK1ΔCRD1-3xF (ΔCRD1), or carrying an empty vector (Vec) in response to oxaliplatin (top) and (bottom). * P \u0026lt; 0.05; ** P \u0026lt; 0.01, n.s. = not significant. Data are mean ± SEM (n = 3). (G) Quantification analysis of tumor sphere size in SW48 cells stably expressing SP-GFP (SP), DKK1-GFP (DKK1), or DKK1ΔCRD1-GFP (ΔCRD1) in response to oxaliplatin. * P \u0026lt; 0.05, **** P \u0026lt; 0.0001, n.s. = not significant. Data are mean ± SEM. A total of 30 tumor spheres were counted in each experimental setting.\u003c/p\u003e","description":"","filename":"Fig41.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4023430/v1/784f569c804b246b56efcc5c.jpg"},{"id":54412524,"identity":"74814b4e-1324-4544-a589-b6d211395a26","added_by":"auto","created_at":"2024-04-10 05:56:21","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":3664522,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eUpregulated DKK1 sustains CRC tumor growth and associates with oxaliplatin resistance.\u003c/strong\u003e (A) Growth curves of xenograft tumors derived from CA01 cells stably expressing SP-GFP or DKK1-GFP. The tumor-bearing mice were treated with mock (n = 6) or administered 5 mg/kg oxaliplatin once per week (n = 6) for 3 weeks. Data are mean ± SEM. (B) Curves of relative tumor volume in xenograft tumors from Fig. 5A. Relative tumor volume was calculated using oxaliplatin-treated tumor volume/mock-treated tumor volume. ** P \u0026lt; 0.01, *** P \u0026lt; 0.001. Data are mean ± SEM. (C) Relative tumor volume at day 17, as described in Fig. 5B, was calculated as oxaliplatin-treated volume/mock-treated volume × 100%. ** P \u0026lt; 0.01. Data are mean ± SEM (n = 6). (D) The percentage of Ki67\u003csup\u003e+\u003c/sup\u003e cells in CA01 xenograft tumors is shown in Fig. 5A. A total of 2000 cells were calculated in each tumor section. *** P \u0026lt; 0.001, n.s. = not significant. Data are mean ± SEM (n = 6). (E) The percentage of TUNEL\u003csup\u003e+\u003c/sup\u003e cells in CA01 xenograft tumors is shown in Fig. 5A. A total of 2000 cells were calculated in each tumor section. *** P \u0026lt; 0.001, n.s. = not significant. Data are mean ± SEM (n = 6). (F) Representative images of IHC analysis of DKK1 expression in patients with CRC. Magnified images of the boxed areas are shown. Scale bar: 50 μm. (G) Fold change in the DKK1 H-score in 12 post-relapse versus pair-matched pre-treatment CRC samples.\u003c/p\u003e","description":"","filename":"Fig51.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4023430/v1/14b2abe9d6630c08d09e2094.jpg"},{"id":54412523,"identity":"5fee0bcf-e55f-4dc7-949a-ba97a441f4b3","added_by":"auto","created_at":"2024-04-10 05:56:21","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":4420018,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eLZ protein suppresses OR CRC cell growth \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003ein vitro\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e and \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003ein vivo\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e.\u003c/strong\u003e (A) Representative western blots of DKK1-GFP coimmunoprecipitated with anti-DeRed antibodies. (n = 3). (B) Representative western blots of endogenous DKK1 coimmunoprecipitated with anti-DeRed antibodies. (n = 3). (C) Percentage of GFP\u003csup\u003e+\u003c/sup\u003e cells in CM treatment experiments on SW48 cells. * P \u0026lt; 0.05. Data are mean ± SEM. (n = 3). (D) Representative images of the CM treatment experiments on SW48 cells, as determined by immunocytochemistry and confocal scanning laser microscopy. Scale bar: 20 μm. (E) Representative images of clonogenic growth assays for CM treatment experiments on LoVo-OR cells (top), quantification analysis of colony number (middle), and representative western blots of mCherry fusion proteins in CM (bottom). * P \u0026lt; 0.05; *** P \u0026lt; 0.001. Data are mean ± SEM (n = 3). (F) Tumor growth curves in mice bearing xenograft tumors originating from LoVo-OR cells treated with 5 mg/kg oxaliplatin once per week (n = 12). When the tumor size reached 100 mm\u003csup\u003e3\u003c/sup\u003e, the tumor-bearing mice were grouped into SP (n = 6) and LZ (n = 6). The SP group had SP-mCherry containing CM, and the LZ group had SP-LZ-mCherry containing CM three times per week for 3 weeks. After CM withdrawal, tumor growth was monitored for an additional 3 weeks. Oxaliplatin was administered throughout the courses. Arrows indicate CM administration. *P \u0026lt; 0.05. Data are mean ± SEM. (G) The percentage of Ki67\u003csup\u003e+\u003c/sup\u003e cells (top) and TUNEL\u003csup\u003e+\u003c/sup\u003e cells (bottom) in LoVo-OR xenograft tumors, as described in Fig. 6F. A total of 2000 cells were counted in each tumor section. * P \u0026lt; 0.05, *** P \u0026lt; 0.001. Data are mean ± SEM (n = 6).\u003c/p\u003e","description":"","filename":"Fig61.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4023430/v1/529c034e43ccd193517923a3.jpg"},{"id":65484396,"identity":"b86c51cb-a774-45d6-b5f7-b71658bffcec","added_by":"auto","created_at":"2024-09-28 07:06:27","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":25579480,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4023430/v1/5cc16bf5-2a66-42b0-8967-558a84004e6f.pdf"},{"id":54412525,"identity":"a7a3b814-4f97-4da0-88df-ef4f0705f449","added_by":"auto","created_at":"2024-04-10 05:56:21","extension":"pdf","order_by":8,"title":"","display":"","copyAsset":false,"role":"supplement","size":1321332,"visible":true,"origin":"","legend":"","description":"","filename":"SupOncogenesubmit0301.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4023430/v1/4da607b3177fda2f5198cc12.pdf"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose.","formattedTitle":"DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eColorectal cancer (CRC) arises from benign polyps, posing challenges due to rising incidence, high mortality, and drug resistance. Surgical resection is the mainstay treatment, yet for unresectable cases or surgery intolerance, drug or radiation therapies are used pre- or post-surgery to shrink tumors or as adjuvant treatments [\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Oxaliplatin, a third-generation platinum-based compound, induces DNA interstrand crosslinks, forming DNA-Pt adducts that disrupt DNA replication, leading to cell cycle arrest and apoptosis. Despite its efficacy, prolonged or repeated use of oxaliplatin often results in drug resistance, adverse events, tumor relapse, and reduced survival in CRC patients [\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Therefore, comprehending how CRC surpasses oxaliplatin treatments is crucial. This insight will aid in devising innovative therapeutic approaches to enhance the clinical care of patients with oxaliplatin-resistant (OR) CRC.\u003c/p\u003e \u003cp\u003eProposed mechanisms for oxaliplatin resistance include alterations in DNA damage response, changes in cell death and survival pathways, and alters in protein expression [\u003cspan additionalcitationids=\"CR8 CR9 CR10\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Pro-survival pathways such as AKT activation have been implicated in preventing cancer cell death. Notably, increased AKT activity have been observed in OR cancer cells, including hepatoma HepG2 cells [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e], colorectal cancer cells [\u003cspan additionalcitationids=\"CR14\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], and cholangiocarcinoma cells [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Inhibiting the PI3K/AKT pathway has shown efficacy in enhancing oxaliplatin sensitivity in OR HepG2 [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] and OR CRC HCT116 cells [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. These studies collectively highlight the critical role of AKT in fostering oxaliplatin resistance in cancer cells.\u003c/p\u003e \u003cp\u003eDickkopf1 (DKK1), initially identified as an embryonic head inducer, holds significant importance in embryo development [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. This secreted protein contains two cysteine-rich domains: CRD1 and CRD2. The CRD1 domain interacts with the leucine zipper (LZ) domain of cytoskeleton-associated protein 4 (CKAP4) [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. The CRD2 domain is required for interaction with low-density lipoprotein receptor-related protein 6 (LRP6), identified as the first DKK1 receptor [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. Canonically, DKK1 acts as a tumor suppressor by inhibiting Wnt signaling [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. It forms a complex with LRP6 or Kremen receptors, leading to β-catenin degradation and Wnt signaling suppression. However, mutations in Wnt signaling components are common in human cancers. Despite its canonical role, DKK1 is often upregulated in various human cancers. A meta-analysis demonstrated that increased DKK1 expression correlates with shorter progression-free survival, disease-free survival, and time to recurrence in various cancers, including digestive system cancers [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Elevated DKK1 levels in tumor tissues are associated with poor prognosis in rectal cancer, non-small cell lung cancer, and esophageal squamous cell carcinoma [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Additionally, high serum DKK1 levels are detected in CRC patients with liver metastasis, correlating with poorer overall survival [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. It shows that DKK1 promotes the invasive ability of cancer cells in both gain- and loss-of-function studies [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. Recent research highlights the involvement of the DKK1-CKAP4 signal axis in tumor progression via AKT activation [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. While DKK1\u0026rsquo;s role in promoting tumor malignant transformation is established, its link to drug resistance development remains underexplored.\u003c/p\u003e \u003cp\u003eTherapeutic strategies targeting the DKK1/CKAP4 interaction are in development. Elevated levels of DKK1 are associated with focal bone lesions in multiple myeloma (MM) [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. Preclinical studies in mice with human MM showed that the humanized DKK1-neutralizing antibody BHQ880 reduced MM cell numbers [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. A phase IB study found that combining BHQ880 with zoledronic acid was tolerated and showed potential clinical activity in MM patients [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. Another humanized DKK1-neutralizing antibody, DKN-01, demonstrated tolerability and clinical activity in phase I studies with advanced biliary cancer, non-small cell lung cancer, esophageal cancer, and gastroesophageal junction tumors [\u003cspan additionalcitationids=\"CR33\" citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. In a phase II study, DKN-01 combined with tislelizumab and chemotherapy improved overall survival in advanced gastroesophageal adenocarcinoma patients [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. Furthermore, anti-CKAP4 monoclonal antibodies effectively blocked the DKK1/CKAP4 interaction, reducing AKT activation, pancreatic cancer cell proliferation, and tumor growth in mouse models [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. Overall, these findings suggest that inhibiting DKK1 signaling holds promise as a cancer therapeutic strategy.\u003c/p\u003e \u003cp\u003eIn our study, we found elevated DKK1 expression in OR CRC cells through protein array analysis. DKK1/CKAP4/AKT signaling activation significantly influences oxaliplatin responses in CRC cell and xenograft tumor models. Knockdown of DKK1 or CKAP4 not only suppresses AKT signaling but also enhances oxaliplatin sensitivity in OR CRC cells. Exposure to DKK1-containing conditional medium stimulates AKT signaling, thus reducing oxaliplatin-induced apoptosis and CRC cell sensitivity to oxaliplatin. Our findings reveal the importance of DKK1's cysteine-rich domain 1 (CRD1) and CKAP4's leucine zipper (LZ) domain in their cell surface interaction. Moreover, the LZ protein effectively disrupts DKK1-CKAP4 interaction, rendering OR CRC cells susceptible to oxaliplatin both in vitro and in vivo xenograft tumors. We suggest that DKK1 promotes chemoresistance in CRC cells by activating AKT signaling. Consequently, targeting DKK1 emerges as a promising therapeutic strategy for CRC patients with oxaliplatin resistance.\u003c/p\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eDKK1 is upregulated in oxaliplatin-resistant colorectal cancer cells\u003c/h2\u003e \u003cp\u003eOR CRC cell lines (LoVo-OR, SW48-OR, and CA01-OR) were created following established protocols [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Utilizing MTS-based assays revealed reduced sensitivity to oxaliplatin compared to parental cells (P) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). Further analysis via tumor sphere formation (Supplementary Fig.\u0026nbsp;1A) and xenograft assays confirmed the robust growth of LoVo-OR cells in the presence of oxaliplatin (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB and Supplementary Fig.\u0026nbsp;1B). To explore molecular factors influencing oxaliplatin responses, we conducted proteomic analysis comparing LoVo-OR and LoVo-P tumor spheres. Utilizing the Proteome Profiler Human XL Oncology Array, we identified 3 downregulated and 4 upregulated proteins in LoVo-OR spheres, notably FGF2 and DKK1 (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC and Supplementary Fig.\u0026nbsp;1C). Dysregulation of FGF signaling is associated with aggressive cancer traits, drug resistance, and poor clinical outcomes [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. However, analysis from the UALCAN database showed that FGF2 upregulation wasn't significantly linked to colon adenocarcinoma (COAD) tissues, tumor stages, lymph node status, or clinical outcomes (Supplementary Fig.\u0026nbsp;1D-G).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eDKK1 is frequently upregulated in various tumors and is associated with poor prognosis in patients [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. Analysis of the UALCAN database showed a significant increase in DKK1 expression in COAD tissues (P\u0026thinsp;=\u0026thinsp;0.0019) across different tumor stages and lymph node statuses (Supplementary Fig.\u0026nbsp;1H-J), suggesting its potential as a diagnostic marker for COAD patients. Although the association between DKK1 mRNA expression and overall survival (OS) in COAD patients was not statistically significant (Supplementary Fig.\u0026nbsp;1K), we aimed to investigate its role in oxaliplatin resistance in CRC.\u003c/p\u003e \u003cp\u003eWestern blotting analysis of CRC tumor spheres demonstrated upregulated DKK1 expression OR cell lines (LoVo-OR, SW48-OR, and CA01-OR) compared to their oxaliplatin-sensitive counterparts (P) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD). As DKK1 is a secreted protein, we examined its levels in the cell culture media. Daily collection of medium samples showed detectable DKK1 protein in both LoVo-P and LoVo-OR cells, with higher levels in LoVo-OR cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE). Enzyme-linked immunosorbent assay (ELISA) quantification normalized against cell numbers confirmed more efficient DKK1 secretion in LoVo-OR cells, with a concentration of secreted DKK1 (sDKK1) measured at 0.084\u0026thinsp;\u0026plusmn;\u0026thinsp;0.023 ng/\u0026micro;l in LoVo-OR cell culture medium on day 3 (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eDownregulation DKK1/CKAP4/AKT signaling facilitates oxaliplatin resistance in colorectal cancer cells\u003c/h2\u003e \u003cp\u003eDKK1 is known to bind, cytoskeleton-associated protein 4 (CKAP4, a membrane protein), activating downstream AKT signaling and facilitating cancer cell proliferation and malignant transformation [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. To explore the involvement of DKK1 signaling in oxaliplatin resistance in CRC, we examined AKT activation, finding a positive correlation with increased DKK1 expression in OR CRC tumor spheres (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD). Using RNA interference (RNAi), we reduced DKK1 expression with two independent DKK1-specific shRNAs (#85 and #88). SW48-OR cells expressing DKK1 shRNAs showed decreased DKK1 expression, leading to reduced phospho-AKT levels at Thr308 and Ser473 (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). DKK1 knockdown inhibited SW48-OR colony formation in soft-agar assays (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB) and significantly reduced the number of SW48-OR tumor spheres in the presence of oxaliplatin (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC). Similar results were observed in LoVo-OR and CA01-OR cells (Supplementary Fig.\u0026nbsp;2A-D), underscoring DKK1's crucial role in activating AKT and modulating oxaliplatin responses in resistant CRC cells.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eSubsequently, UALCAN database analysis revealed elevated CKAP4 expression in COAD tissues (P\u0026thinsp;=\u0026thinsp;0.0016), significant across tumor stages and lymph node status (Supplementary Fig.\u0026nbsp;2E-G). Although the association between CKAP4 mRNA expression and overall survival (OS) in COAD patients wasn't statistically significant (Supplementary Fig.\u0026nbsp;2H), we investigated CKAP4's role in mediating DKK1-stimulated AKT signaling. SW48-OR cells expressing CKAP4 shRNAs exhibited decreased CKAP4 expression, reduced AKT activity, and impaired colony and tumor sphere formation compared to controls with scrambled shRNAs (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eD-F). Similar effects were seen in LoVo-OR and CA01-OR cells (Supplementary Fig.\u0026nbsp;2I-L). In conclusion, our findings suggest that DKK1/CKAP4/AKT signaling axis is upregulated in oxaliplatin-resistant CRC cells and plays a crucial role in promoting cell growth in the presence of oxaliplatin.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eSecreted DKK1-mediated activation of AKT signaling via CKAP4 in colorectal cancer cells\u003c/h2\u003e \u003cp\u003eThe DKK1/CKAP4/AKT signaling axis's impact on cancer biology has been previously demonstrated by manipulating cellular DKK1 expression levels [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. We aimed to address the function of secreted DKK1 (sDKK1) in CRC cells. sDKK1-containing conditioned media (CM) was obtained from 293 cells expressing 3xFlag-tagged DKK1 (DKK1-3xF, Supplementary Fig.\u0026nbsp;3A) after a 3-day serum-free medium incubation. Levels of DKK1-3xF in CM were assessed via western blotting (Supplementary Fig.\u0026nbsp;3B) and ELISA. Time-course CM treatment of SW48 cells revealed significant AKT activation at the 30-minute mark with DKK1-3xF, contrasting with negligible effects observed with mock CM (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA). To assess sDKK1\u0026rsquo;s interaction with the CKAP4 receptor, we employed a truncated form of DKK1 lacking CRD1 (DKK1ΔCRD1-3xF; Supplementary Fig.\u0026nbsp;3A), responsible for CKAP4 interaction [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. CM containing DKK1ΔCRD1-3xF (ΔCRD1-3xF) was collected and leveled (Supplementary Fig.\u0026nbsp;3B), revealing reduced DKK1-induced AKT phosphorylation in SW48 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA), similarly observed in CA01 cells (Supplementary Fig.\u0026nbsp;3C). Subsequently, we explored CKAP4\u0026rsquo;s role in mediating sDKK1-induced AKT signaling. SW48 cells expressing shRNAs against CKAP4 treated with DKK1-3xF-containing CM showed partially attenuated DKK1-3xF-induced phospho-AKT levels (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB), suggesting CKAP4\u0026rsquo;s involvement in mediating sDKK1-activated AKT.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eAdditionally, to visualize sDKK1's interaction with CKAP4 on the plasma membrane, we generated a DKK1-GFP fusion protein, where GFP was tagged at DKK1\u0026rsquo;s C-terminus. The signal peptide (SP) [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e] derived from DKK1 was fused to the N-terminus of GFP (SP-GFP) for GFP secretion guidance, serving as a control (Supplementary Fig.\u0026nbsp;3A). CM collected from 293 cells expressing SP-GFP (SP), DKK1-GFP (DKK1), or DKK1ΔCRD1-GFP (ΔCRD1) was analyzed and leveled (Supplementary Fig.\u0026nbsp;3D). Flow cytometry analysis of SW48 cells incubated with CM revealed a significant decrease in GFP\u0026thinsp;+\u0026thinsp;cells with ΔCRD1 CM compared to DKK1 CM (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC and Supplementary Fig.\u0026nbsp;3E). Plasma membrane isolation assays confirmed DKK1 presence in the plasma membrane fraction, with reduced levels for ΔCRD1, supporting sDKK1\u0026rsquo;s binding to the cell plasma membrane, attenuated by CRD1 truncation (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD). To validate CKAP4\u0026rsquo;s role in sDKK1-cell interactions, flow cytometry analysis of SW48 cells expressing shRNAs against CKAP4 incubated with DKK1 CM revealed reduced GFP\u0026thinsp;+\u0026thinsp;cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eE and Supplementary Fig.\u0026nbsp;3F). Immunocytochemistry (ICC) analysis further confirmed sDKK1's association with the plasma membrane and CKAP4, with colocalization observed and reduced by CRD1 truncation (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eF). These findings support CRD1\u0026rsquo;s critical role in sDKK1 interaction with CKAP4 on the cell surface to activate AKT signaling.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003esDKK1 modulates oxaliplatin responses in CRC cells\u003c/h2\u003e \u003cp\u003eNext, we investigated the impact of sDKK1 on oxaliplatin responses in CRC cells via the CKAP4/AKT pathway. CM containing sDKK1 was obtained from 293 cells expressing DKK1-3xF, DKK1ΔCRD1-3xF (ΔCRD1-3xF), or an empty vector (Mock). SW48 cells treated with 0.1 \u0026micro;M oxaliplatin for 24 hours, followed by a 30-minute CM incubation. Western blotting showed increased phospho-AKT levels with DKK1-3xF CM, partially restoring oxaliplatin-inhibited AKT phosphorylation, weakened by CRD1 truncation (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). MTS assays indicated no significant effect on cell proliferation, but DKK1-3xF CM partially rescued oxaliplatin-inhibited cell growth (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB). Similar results were observed in CA01 cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC and D). Apoptosis assays in SW48 cells showed DKK1-3xF CM minimized oxaliplatin-induced early apoptosis compared to mock or ΔCRD1-3xF CM (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eE and Supplementary Fig.\u0026nbsp;4A). Long-term focus formation assays in SW48 cells stably expressing DKK1-3xF and ΔCRD1-3xF indicated DKK1 expression partially rescued cells from oxaliplatin treatment (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eF and Supplementary Fig.\u0026nbsp;4B). Anchorage-independent cell growth assays in SW48 cells demonstrated DKK1 expression partially restored oxaliplatin-suppressed sphere growth, whereas ΔCRD1 did not (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG and Supplementary Fig.\u0026nbsp;4C). These findings collectively suggest sDKK1 contributes to modulating oxaliplatin responses through the CKAP4/AKT pathway.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eDKK1 sustains CRC tumor growth in the presence of oxaliplatin\u003c/h2\u003e \u003cp\u003eIn a study on CRC's oxaliplatin resistance, CA01 cells expressing SP-GFP (SP) or DKK1-GFP (DKK1) were xenografted into mice. Mice received mock or oxaliplatin injections (5 mg/kg) weekly for 3 weeks. DKK1-GFP expression had no significant effect on tumor volume. However, oxaliplatin notably reduced tumor volume in SP-GFP tumors, whereas DKK1-GFP tumors-maintained growth (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA and B). By treatment end, SP-GFP tumors decreased while DKK1-GFP tumors increased in size (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eC). Immunohistochemistry (IHC) analysis revealed a decrease in Ki67\u0026thinsp;+\u0026thinsp;cells to 33.7\u0026thinsp;\u0026plusmn;\u0026thinsp;8.5% and an increase in TUNEL\u0026thinsp;+\u0026thinsp;cells to 9.4\u0026thinsp;\u0026plusmn;\u0026thinsp;1.5% in SP-GFP tumors, whereas these responses were attenuated in DKK1-GFP tumors (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eD and E, and Supplementary Fig.\u0026nbsp;5A and B). To confirm DKK1-GFP secretion in tumor-bearing mice, blood plasma underwent immunoprecipitation with anti-GFP antibodies and protein A/G beads. Western blotting confirmed GFP fusion protein presence, indicating SP-GFP and DKK1-GFP secretion from tumors into the blood (Supplementary Fig.\u0026nbsp;5C).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eFindings from SW48 cells expressing DKK1-3xF (WT), DKK1ΔCRD1-3xF (ΔCRD1), or empty vector (Vec) mirrored those in CA01 xenograft tumors. DKK1 or ΔCRD1 expression didn't significantly enhance SW48 xenograft growth. Oxaliplatin notably reduced tumor volume in ΔCRD1 or Vec tumors, while DKK1-expressing tumors remained stable (Supplementary Fig.\u0026nbsp;5D and E). By treatment end, ΔCRD1 and Vec tumors decreased in size, while DKK1 tumors increased (Supplementary Fig.\u0026nbsp;5F). Animal body weights remained consistent throughout treatment (Supplementary Fig.\u0026nbsp;5G). These findings support elevated DKK1 sustaining CRC tumor growth in oxaliplatin presence, indicating its key role in oxaliplatin resistance in colorectal cancer.\u003c/p\u003e \u003cp\u003eTo associate DKK1 expression with oxaliplatin resistance onset in CRC patients, we conducted IHC on 12 pairs of pre-treatment and post-relapse tumor samples from oxaliplatin-treated patients (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eF). DKK1 expression was quantified using the IHC H-score. Statistical analysis revealed a significant difference in DKK1 expression between pre-treatment and post-relapse CRC samples (p\u0026thinsp;=\u0026thinsp;0.0197, Supplementary Fig.\u0026nbsp;5H). Normalizing DKK1 H-scores from 12 post-relapse samples against their pre-treatment counterparts yielded fold changes in DKK1 expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eG). Remarkably, increased DKK1 H-scores (fold change\u0026thinsp;\u0026gt;\u0026thinsp;1.0) were found in 9 OR CRCs, constituting 75% of the total 12 CRCs. Among these, 6 OR CRCs (50% of the total 12 CRCs) exhibited over a 2-fold increase in DKK1 H-score (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eG). These results strongly suggest a positive association between DKK1 expression and oxaliplatin resistance development in CRC.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eLZ protein suppresses oxaliplatin-resistant CRC cell growth\u003c/h2\u003e \u003cp\u003eOur findings suggest that the crucial role of the DKK1/CKAP4 interaction in regulating oxaliplatin responses in CRC cell lines, indicating a potential therapeutic strategy for suppressing OR CRC cell growth. Given the reported requirement for the LZ domain in CKAP4 and the CRD1 in DKK1 for their interaction [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e], we investigated the disruptive potential of an LZ domain-containing protein.\u003c/p\u003e \u003cp\u003eWe cloned a one-hundred-amino-acid region overlapping the defined LZ domain (aa 468\u0026ndash;503) of CKAP4 [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e], generating a secreted form of the SP-LZ-mCherry fusion protein (LZ protein) (Supplementary Fig.\u0026nbsp;6A). CM containing LZ protein or SP-mCherry was collected, confirmed, and normalized for consistency (Supplementary Fig.\u0026nbsp;6B). To assess the interaction of the LZ protein with sDKK1 via CRD1, immunoprecipitation assays were performed using anti-DsRed antibodies with CMs containing DKK1-GFP and LZ protein. The results revealed GFP fusion proteins in the anti-DsRed immunoprecipitation complex in DKK1-GFP CM, with diminished levels in DKK1ΔCRD1-GFP CM (Supplementary Fig.\u0026nbsp;6C), suggesting that the CRD1 mainly facilitates the interaction between the LZ protein and sDKK1. Further validation of the specificity of the LZ protein/sDKK1 interaction was achieved, demonstrating the specific interaction of the LZ protein with both exogenously expressed DKK1-GFP and endogenous sDKK1 proteins (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA and B). To assess the impact of the LZ protein on the binding of sDKK1 to CKAP4 on the cell surface, flow cytometry and ICC analyses were performed using SW48 cells incubated with DKK1-GFP\u0026thinsp;+\u0026thinsp;SP-mCherry CM or DKK1-GFP\u0026thinsp;+\u0026thinsp;LZ protein CM for 30 minutes. The percentage of GFP\u0026thinsp;+\u0026thinsp;cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eC and Supplementary Fig.\u0026nbsp;6D) and the association of sDKK1-GFP with the cell surface (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eD) were reduced by the presence of LZ protein CM, contrasting with SP-mCherry. These results suggest that the LZ protein functions by sequestering sDKK1, thereby interfering with the binding of sDKK1 to CKAP4 on the cell surface.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWe then evaluated the LZ protein's therapeutic potential in inhibiting OR CRC growth. Long-term focus formation assays demonstrated significantly inhibited colony formation in LoVo-OR cells when exposed to LZ protein CM compared to SP-mCherry (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eE). To validate these findings, LoVo-OR cells were xenografted into mice, divided into SP and LZ groups, and administrated SP-mCherry CM and LZ protein CM three times per week for 3 weeks. After CM withdrawal, tumor growth was monitored for an additional 3 weeks with continuous oxaliplatin administration (Supplementary Fig.\u0026nbsp;6E). Notably, LoVo-OR tumor growth was significantly suppressed in the LZ group compared to the SP group, and this effect persisted for up to 3 weeks after discontinuing LZ protein CM administration (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eF and Supplementary Fig.\u0026nbsp;6F). Importantly, there were no discernible effects on the mice\u0026rsquo;s body weight (Supplementary Fig.\u0026nbsp;6G), suggesting the safety of CM administration. Additionally, IHC analysis of tumor samples revealed a reduced percentage of actively proliferating tumor cells (96.9\u0026thinsp;\u0026plusmn;\u0026thinsp;0.9% in SP, and 59.4\u0026thinsp;\u0026plusmn;\u0026thinsp;6.5% in LZ) and an increased percentage of apoptotic cells (0.8\u0026thinsp;\u0026plusmn;\u0026thinsp;0.4 in SP, and 12.5\u0026thinsp;\u0026plusmn;\u0026thinsp;4.8% in LZ) in the LZ group (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eG, and Supplementary Fig.\u0026nbsp;6H and I). These findings collectively support the LZ protein's inhibitory effect on oxaliplatin-resistant CRC growth, suggesting a promising therapeutic strategy for CRC characterized by elevated DKK1 levels.\u003c/p\u003e \u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eOur study reveals a clear link between DKK1 expression and oxaliplatin resistance in colorectal cancer. DKK1 secretion is notably higher in OR CRC cells compared to parental cells. Clinically, DKK1 expression is significantly elevated in post-relapse tumors from patients on oxaliplatin-based chemotherapy, suggesting its role in resistance development in CRC. Mechanistically, we demonstrated that secreted DKK1 (sDKK1) activates AKT by binding CKAP4 on the cell membrane. This DKK1 signaling shields CRC cells from oxaliplatin-induced cytotoxicity, causing oxaliplatin resistance in vitro and in vivo. Importantly, blocking the DKK1/CKAP4 interaction with the LZ protein heightened OR CRC cells' sensitivity to oxaliplatin and inhibited OR CRC xenograft tumor growth. In summary, our findings highlight two main points: 1) DKK1 signaling is pivotal in regulating oxaliplatin responses in CRC, and 2) inhibiting the DKK1/CKAP4 interaction using the LZ domain could be a promising therapy for oxaliplatin-resistant CRC.\u003c/p\u003e \u003cp\u003eAKT activation is intricately regulated by diverse upstream pathways, notably phosphatidylinositol-3-kinase (PI3K), which regulates fundamental cellular processes like apoptosis, proliferation, and differentiation. This pathway, notorious for driving malignant transformation, is implicated in key cancer features. Moreover, AKT activation is strongly linked to drug resistance in various cancers[\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e, \u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e], including cisplatin-resistant lung cancer [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e], acquired resistance to standard therapies breast cancer [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e], and BRAF inhibitor-resistant melanoma [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]. Our study revealed that sDKK1's role in stimulating AKT activation in oxaliplatin resistance. Exploring DKK1 signaling in other AKT-driven drug-resistant cancers and assessing the LZ protein's effects could be promising future research directions.\u003c/p\u003e \u003cp\u003eClinical studies link higher DKK1 levels with shorter recurrence times and poorer prognosis in patients[\u003cspan additionalcitationids=\"CR22\" citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Elevated DKK1 is seen in CRC patients with liver metastasis, correlating with reduced overall survival[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. Both gain- and loss-of-function studies show DKK1\u0026rsquo;s role in tumor progression and malignant transformation through the DKK1/CKAP4/AKT signaling [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. In our study, while DKK1 minimally affects CRC tumor growth, the DKK1/CKAP4/AKT axis significantly influences oxaliplatin responses, including cell proliferation, colony formation, anchorage-independent cell growth, apoptosis, and xenograft tumor growth in different CRC cell lines.\u003c/p\u003e \u003cp\u003eIt's proposed that DKK1's CRD1 and CKAP4's LZ domain are crucial for their interaction, supported by immunoprecipitation-western blot (IP-WB) assays using cell lysates from cells expressing variants of DKK1 or CKAP4 [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. To explore their cell surface interaction, we utilized GFP-tagged DKK1 in conditioned medium to visualize sDKK1 binding to the cell membrane. Our findings highlight the essential role of CRD1 in sDKK1's association with CKAP4 on the cell surface, as evidenced by reduced AKT activity, membrane association, and modulation of oxaliplatin responses upon incubation with CRD1-truncated DKK1. This underscores the therapeutic potential of targeting the DKK1/CKAP4 interaction in OR CRCs.\u003c/p\u003e \u003cp\u003eIn our strategy, rather than creating DKK1-neutralizing antibodies, we designed an SP-LZ-mCherry fusion protein, utilizing the signal peptide (SP) to guide LZ-mCherry secretion. These secreted LZ proteins interact efficiently with DKK1, disrupting the DKK1/CKAP4 interaction on the cell membrane. This approach effectively inhibits colony formation and xenograft tumor growth in OR CRC cells, highlighting the LZ protein's therapeutic promise for OR CRC. Future research will assess the LZ protein's anti-tumor efficacy in DKK1-overexpressing cancers. Notably, DKK1's association with a suppressive tumor immune microenvironment (TIME) and its potential as an immunotherapeutic target are significant[\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e]. Therefore, investigating the LZ protein's impact on DKK1-mediated TIME modulation is crucial. Our study presents a novel approach to dampen DKK1 signaling via the LZ protein, offering a convenient method for generating LZ fusion proteins through SP-directed protein secretion.\u003c/p\u003e \u003cp\u003eOur study not only unveiled a positive association between the expression of DKK1 and the development of oxaliplatin resistance in colorectal cancer (CRC) but also elucidated the molecular mechanism through which the DKK1/CKAP4 interaction modulates oxaliplatin responses. Furthermore, our results strongly indicate that attenuating the DKK1/CKAP4/AKT signaling axis using the LZ protein effectively suppressed oxaliplatin-resistant (OR) CRC cell growth both \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003ein vivo\u003c/em\u003e (Supplementary Fig.\u0026nbsp;6J). This finding holds promise as a potential therapeutic strategy for the treatment of OR CRC.\u003c/p\u003e"},{"header":"MATERIALS AND METHODS","content":"\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003ePatient samples and establishment of a colorectal cancer cell line\u003c/h2\u003e \u003cp\u003e Patients provided signed informed consent prior to their inclusion in this study, which was approved by the institutional review board at the National Cheng Kung University Hospital (B-BR-106-068, NCKUH, Tainan, Taiwan). Patients with CRC were enrolled and received oxaliplatin-based chemotherapy. The pre-treatment tumor biopsies were performed, and pair-matched post-relapse tumor biopsies were collected at the time of progression.\u003c/p\u003e \u003cp\u003eNo statistical method was used to predetermine the sample size. No samples were excluded. The formalin-fixed tissue was analyzed to confirm the presence of viable tumor by hematoxylin and eosin (H\u0026amp;E) staining.\u003c/p\u003e \u003cp\u003eTo generate a primary CRC cell line, CA01, the procedures were performed as previously described [\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e]. Briefly, a tumor section was excised from a 63-year-old Taiwanese woman who underwent surgical operations at NCKU in 2020 (0140140-2). The sample was mechanically fragmented and enzymatically digested. Cells were collected and cultured in DMEM/F-12 medium (Gibco, Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 100 U/ml of penicillin\u0026ndash;streptomycin (Gibco) for further experiments.\u003c/p\u003e \u003cp\u003e \u003cb\u003eIn vivo\u003c/b\u003e \u003cb\u003exenograft tumor growth studies\u003c/b\u003e\u003c/p\u003e \u003cp\u003e Mice were maintained in accordance with facility guidelines on animal welfare and with protocols approved by the Institutional Animal Care and Usage Committee (IACUC) of the National Cheng Kung University. Four- to 6-week-old female NOD/SCID mice (NCKU, Tainan, Taiwan) were housed in a specific pathogen-free environment in the animal facility of NCKU. For oxaliplatin sensitivity assays, 1 \u0026times; 10\u003csup\u003e7\u003c/sup\u003e LoVo-P or LoVo-OR cells were mixed with Matrigel (1:1, BD Biosciences, Franklin Lakes, NJ, USA) and subcutaneously inoculated into the flanks of the mice. LoVo-OR tumor-bearing mice (n\u0026thinsp;=\u0026thinsp;3) were administered oxaliplatin (5 mg/kg) once per week for 6 weeks by intraperitoneal injection. The LoVo-P tumor-bearing mice were grouped into mock (n\u0026thinsp;=\u0026thinsp;3) and OXA (n\u0026thinsp;=\u0026thinsp;3) groups when tumor size reached 100 mm\u003csup\u003e3\u003c/sup\u003e. The mock group was administered PBS, and the OXA group was given 5 mg/kg oxaliplatin once per week for 6 weeks by intraperitoneal injection.\u003c/p\u003e \u003cp\u003eTo evaluate the effects of DKK1 on oxaliplatin sensitivity, 2 x 10\u003csup\u003e6\u003c/sup\u003e CA01 cells stably expressing SP-GFP or DKK1-GFP were grown as xenograft tumors. When tumor size reached 100 mm\u003csup\u003e3\u003c/sup\u003e, mice were randomly assigned to two groups: mock (n\u0026thinsp;=\u0026thinsp;6) and OXA (n\u0026thinsp;=\u0026thinsp;6). The mock group was administered PBS, and the OXA group was administered 5 mg/kg oxaliplatin once per week for 3 weeks by intraperitoneal injection. In addition, 2 x 10\u003csup\u003e6\u003c/sup\u003e SW48 cells stably expressing DKK1-3xF, DKK1ΔCRD1-3xF, or carrying an empty vector were grown as xenograft tumors. The tumor-bearing mice were randomly assigned to two groups: mock (n\u0026thinsp;=\u0026thinsp;6) and OXA (n\u0026thinsp;=\u0026thinsp;6). The mock group was administered PBS, and the OXA group was administered 5 mg/kg oxaliplatin once per week for 3 weeks by intraperitoneal injection.\u003c/p\u003e \u003cp\u003eTo address the impact of the LZ protein on suppressing oxaliplatin-resistant tumor growth, 1 \u0026times; 10\u003csup\u003e7\u003c/sup\u003e LoVo-OR cells were subcutaneously inoculated into the flanks of the mice. The mice were administered 5 mg/kg oxaliplatin once per week. When the tumor size reached 100 mm\u003csup\u003e3\u003c/sup\u003e, the tumor-bearing mice were randomly assigned to two groups: SP (n\u0026thinsp;=\u0026thinsp;6) and LZ (n\u0026thinsp;=\u0026thinsp;6). The SP group was intraperitoneally injected with SP-mCherry containing CM and the LZ group was administered SP-LZ-mCherry containing CM three times per week for 3 weeks. After CM withdrawal, the tumor growth was monitored for an additional 3 weeks. Oxaliplatin was administered throughout the courses.\u003c/p\u003e \u003cp\u003eThe tumor-bearing mice were randomly grouped using Research Randomizer at \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.randomizer.org\u003c/span\u003e\u003cspan address=\"http://www.randomizer.org\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. The sample size was not statistically determined. Tumors and body weight were monitored daily. Tumor size was calculated using the following formula: volume = [length \u0026times; (width)\u0026sup2;] / 2. The relative tumor volume was determined by dividing the volume of oxaliplatin-treated tumors by that of mock-treated tumors. When the tumor size reached 1000 mm\u0026sup3;, the mice were humanely euthanized. The investigators were not blinded to group allocation or outcome assessment, and no animals were excluded from the experiments.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eStatistics\u003c/h2\u003e \u003cp\u003eStatistical analyses were performed using Prism 8 (GraphPad Software, New York City, NY, USA). The in vitro experiments were performed in biological triplicate each time and independently repeated at least 3 times. Data are presented as the mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SEM and the number (n) of samples used was as indicated. An unpaired two-tailed Student\u0026rsquo;s t-test was used to compare differences between the control and experimental groups, unless otherwise indicated. For all statistical analyses, differences were labeled as *, P\u0026thinsp;\u0026lt;\u0026thinsp;0.05; **, P\u0026thinsp;\u0026lt;\u0026thinsp;0.01; *** P\u0026thinsp;\u0026lt;\u0026thinsp;0.001; ****; n.s. = not significant. P values\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered statistically significant.\u003c/p\u003e \u003c/div\u003e "},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eDATA AVAILABILITY\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll materials are available upon reasonable request to [email protected].\u003c/p\u003e\n\u003cp\u003e \u003ch2\u003eCOMPETING INTERESTS\u003c/h2\u003e \u003cp\u003eThe authors have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFUNDING\u003c/h2\u003e \u003cp\u003eThis research was supported by the National Health Research Institutes, Taiwan (CA-112-PP-23 to CHS), National Science and Technology Council, Taiwan (MOST 110-2314-B-400-019-MY3 to CHS), and Taipei Veterans General Hospital (V112C-137 to NJC).\u003c/p\u003e\u003ch2\u003eAUTHOR CONTRIBUTIONS\u003c/h2\u003e \u003cp\u003eCCH: Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing-review \u0026amp; editing. TWL: Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing-review \u0026amp; editing. CCL: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing-review \u0026amp; editing. SHC: Formal analysis, Investigation, Resources, Writing-review \u0026amp; editing. YLW: Data curation, Formal analysis, Methodology, Writing-review \u0026amp; editing. NJC: Conceptualization, Formal analysis, Funding acquisition, Investigation, Resources, Writing-review \u0026amp; editing. CHS: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing-original draft preparation.\u003c/p\u003e\u003ch2\u003eACKNOWLEDGMENTS\u003c/h2\u003e \u003cp\u003eWe thank the support from the Human Biobank, Research Center of Clinical Medicine and the Cancer Data Bank of National Cheng Kung University Hospital, Taiwan. We thank the technical services provided by the Bio-image Core Facility of the National Core Facility Program for Biotechnology, Ministry of Science and Technology, Taiwan.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eKuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG\u003cem\u003e et al\u003c/em\u003e. Colorectal cancer. \u003cem\u003eNature Reviews Disease Primers\u003c/em\u003e 2015; 1: 15065.\u003c/li\u003e\n\u003cli\u003eBrown KGM, Solomon MJ, Mahon K, O\u0026apos;Shannassy S. Management of colorectal cancer. \u003cem\u003eBMJ\u003c/em\u003e 2019; 366: l4561.\u003c/li\u003e\n\u003cli\u003eVan Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group EGW. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. \u003cem\u003eAnn Oncol\u003c/em\u003e 2014; 25 Suppl 3: iii1-9.\u003c/li\u003e\n\u003cli\u003eArango D, Wilson AJ, Shi Q, Corner GA, Ara\u0026ntilde;es MJ, Nicholas C\u003cem\u003e et al\u003c/em\u003e. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. \u003cem\u003eBritish Journal of Cancer\u003c/em\u003e 2004; 91: 1931-1946.\u003c/li\u003e\n\u003cli\u003eDi Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. \u003cem\u003eCellular and Molecular Life Sciences CMLS\u003c/em\u003e 2002; 59: 1914-1927.\u003c/li\u003e\n\u003cli\u003eIbrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. \u003cem\u003eOncologist\u003c/em\u003e 2004; 9: 8-12.\u003c/li\u003e\n\u003cli\u003eHsieh CC, Hsu SH, Lin CY, Liaw HJ, Li TW, Jiang KY\u003cem\u003e et al\u003c/em\u003e. CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer. \u003cem\u003eBr J Cancer\u003c/em\u003e 2022; 127: 1615-1628.\u003c/li\u003e\n\u003cli\u003eComella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. \u003cem\u003eTher Clin Risk Manag\u003c/em\u003e 2009; 5: 229-238.\u003c/li\u003e\n\u003cli\u003ePanczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. \u003cem\u003eWorld J Gastroenterol\u003c/em\u003e 2014; 20: 9775-9827.\u003c/li\u003e\n\u003cli\u003eKline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. \u003cem\u003ePharmaceuticals (Basel)\u003c/em\u003e 2013; 6: 988-1038.\u003c/li\u003e\n\u003cli\u003eMartinez-Balibrea E, Martinez-Cardus A, Gines A, Ruiz de Porras V, Moutinho C, Layos L\u003cem\u003e et al\u003c/em\u003e. Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance. \u003cem\u003eMol Cancer Ther\u003c/em\u003e 2015; 14: 1767-1776.\u003c/li\u003e\n\u003cli\u003eXu R, Zhang Y, Li A, Ma Y, Cai W, Song L\u003cem\u003e et al\u003c/em\u003e. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1alpha pathway. \u003cem\u003eMol Med Rep\u003c/em\u003e 2021; 24.\u003c/li\u003e\n\u003cli\u003ePark SY, Chung YS, Park SY, Kim SH. Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer. \u003cem\u003eBiomedicines\u003c/em\u003e 2022; 10.\u003c/li\u003e\n\u003cli\u003eWei W, Ma XD, Jiang GM, Shi B, Zhong W, Sun CL\u003cem\u003e et al\u003c/em\u003e. The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1. \u003cem\u003eOncol Res\u003c/em\u003e 2020; 28: 423-438.\u003c/li\u003e\n\u003cli\u003eYu T, An Q, Cao X-L, Yang H, Cui J, Li Z-J\u003cem\u003e et al\u003c/em\u003e. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway. \u003cem\u003eLife Sciences\u003c/em\u003e 2020; 260: 118294.\u003c/li\u003e\n\u003cli\u003eLeelawat K, Narong S, Udomchaiprasertkul W, Leelawat S, Tungpradubkul S. Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. \u003cem\u003eCancer Cell Int\u003c/em\u003e 2009; 9: 3.\u003c/li\u003e\n\u003cli\u003eNiehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. \u003cem\u003eOncogene\u003c/em\u003e 2006; 25: 7469-7481.\u003c/li\u003e\n\u003cli\u003eGlinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. \u003cem\u003eNature\u003c/em\u003e 1998; 391: 357-362.\u003c/li\u003e\n\u003cli\u003eKimura H, Fumoto K, Shojima K, Nojima S, Osugi Y, Tomihara H\u003cem\u003e et al\u003c/em\u003e. CKAP4 is a Dickkopf1 receptor and is involved in tumor progression. \u003cem\u003eJ Clin Invest\u003c/em\u003e 2016; 126: 2689-2705.\u003c/li\u003e\n\u003cli\u003eMao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A\u003cem\u003e et al\u003c/em\u003e. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. \u003cem\u003eNature\u003c/em\u003e 2001; 411: 321-325.\u003c/li\u003e\n\u003cli\u003eHuang J, Lu T, Kuang W. Prognostic role of dickkopf-1 in patients with cancer. \u003cem\u003eMedicine (Baltimore)\u003c/em\u003e 2020; 99: e20388.\u003c/li\u003e\n\u003cli\u003eYamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M\u003cem\u003e et al\u003c/em\u003e. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. \u003cem\u003eCancer Res\u003c/em\u003e 2007; 67: 2517-2525.\u003c/li\u003e\n\u003cli\u003eKemik O, Kemik AS, Sumer A, Begenik H, Purisa S, Tuzun S\u003cem\u003e et al\u003c/em\u003e. Relationship Between Clinicopathologic Variables and Serum and Tissue Levels of Dickkopf-1 in Patients With Rectal Cancer. \u003cem\u003eJournal of Investigative Medicine\u003c/em\u003e 2011; 59: 947.\u003c/li\u003e\n\u003cli\u003eSui Q, Zheng J, Liu D, Peng J, Ou Q, Tang J\u003cem\u003e et al\u003c/em\u003e. Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study. \u003cem\u003eBMC Cancer\u003c/em\u003e 2019; 19: 1210.\u003c/li\u003e\n\u003cli\u003eKagey MH, He X. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. \u003cem\u003eBr J Pharmacol\u003c/em\u003e 2017; 174: 4637-4650.\u003c/li\u003e\n\u003cli\u003eChen L, Li M, Li Q, Wang C-j, Xie S-q. DKK1 promotes hepatocellular carcinoma cell migration and invasion through \u0026beta;-catenin/MMP7 signaling pathway. \u003cem\u003eMolecular Cancer\u003c/em\u003e 2013; 12: 157.\u003c/li\u003e\n\u003cli\u003eIguchi K, Sada R, Matsumoto S, Kimura H, Zen Y, Akita M\u003cem\u003e et al\u003c/em\u003e. DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness. \u003cem\u003eCancer Sci\u003c/em\u003e 2023; 114: 2063-2077.\u003c/li\u003e\n\u003cli\u003eShinno N, Kimura H, Sada R, Takiguchi S, Mori M, Fumoto K\u003cem\u003e et al\u003c/em\u003e. Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug. \u003cem\u003eOncogene\u003c/em\u003e 2018; 37: 3471-3484.\u003c/li\u003e\n\u003cli\u003eTian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B\u003cem\u003e et al\u003c/em\u003e. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. \u003cem\u003eN Engl J Med\u003c/em\u003e 2003; 349: 2483-2494.\u003c/li\u003e\n\u003cli\u003eFulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA\u003cem\u003e et al\u003c/em\u003e. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. \u003cem\u003eBlood\u003c/em\u003e 2009; 114: 371-379.\u003c/li\u003e\n\u003cli\u003eIyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R\u003cem\u003e et al\u003c/em\u003e. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. \u003cem\u003eBr J Haematol\u003c/em\u003e 2014; 167: 366-375.\u003c/li\u003e\n\u003cli\u003eEdenfield WJ, Richards DA, Vukelja SJ, Weiss GJ, Sirard CA, Landau SB\u003cem\u003e et al\u003c/em\u003e. A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer. \u003cem\u003eJournal of Clinical Oncology\u003c/em\u003e 2014; 32: 8068-8068.\u003c/li\u003e\n\u003cli\u003eEads J, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana AA\u003cem\u003e et al\u003c/em\u003e. Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC). \u003cem\u003eAnnals of Oncology\u003c/em\u003e 2016; 27.\u003c/li\u003e\n\u003cli\u003eRyan DP, Murphy J, Mahalingam D, Strickler J, Stein S, Sirard C\u003cem\u003e et al\u003c/em\u003e. PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). \u003cem\u003eAnnals of Oncology\u003c/em\u003e 2016; 27.\u003c/li\u003e\n\u003cli\u003eKlempner SJ, Sirard C, Chao J, Chiu V, Mahalingam D, Uronis H\u003cem\u003e et al\u003c/em\u003e. 1384P DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial. \u003cem\u003eAnnals of Oncology\u003c/em\u003e 2021; 32: S1048-S1049.\u003c/li\u003e\n\u003cli\u003eKimura H, Yamamoto H, Harada T, Fumoto K, Osugi Y, Sada R\u003cem\u003e et al\u003c/em\u003e. CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy. \u003cem\u003eClin Cancer Res\u003c/em\u003e 2019; 25: 1936-1947.\u003c/li\u003e\n\u003cli\u003eAkl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM\u003cem\u003e et al\u003c/em\u003e. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. \u003cem\u003eOncotarget\u003c/em\u003e 2016; 7: 44735-44762.\u003c/li\u003e\n\u003cli\u003eKikuchi A, Fumoto K, Kimura H. The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy. \u003cem\u003eBr J Pharmacol\u003c/em\u003e 2017; 174: 4651-4665.\u003c/li\u003e\n\u003cli\u003eKikuchi A, Matsumoto S, Sada R. Dickkopf signaling, beyond Wnt-mediated biology. \u003cem\u003eSemin Cell Dev Biol\u003c/em\u003e 2022; 125: 55-65.\u003c/li\u003e\n\u003cli\u003eBhavanasi D, Speer KF, Klein PS. CKAP4 is identified as a receptor for Dickkopf in cancer cells. \u003cem\u003eJ Clin Invest\u003c/em\u003e 2016; 126: 2419-2421.\u003c/li\u003e\n\u003cli\u003eFedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP\u003cem\u003e et al\u003c/em\u003e. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. \u003cem\u003eJ Biol Chem\u003c/em\u003e 1999; 274: 19465-19472.\u003c/li\u003e\n\u003cli\u003eAvan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. \u003cem\u003eWorld J Clin Oncol\u003c/em\u003e 2016; 7: 352-369.\u003c/li\u003e\n\u003cli\u003eLiu R, Chen Y, Liu G, Li C, Song Y, Cao Z\u003cem\u003e et al\u003c/em\u003e. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. \u003cem\u003eCell Death Dis\u003c/em\u003e 2020; 11: 797.\u003c/li\u003e\n\u003cli\u003eZhang Y, Bao C, Mu Q, Chen J, Wang J, Mi Y\u003cem\u003e et al\u003c/em\u003e. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells. \u003cem\u003eNeoplasma\u003c/em\u003e 2016; 63: 362-370.\u003c/li\u003e\n\u003cli\u003eDong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. \u003cem\u003eFront Pharmacol\u003c/em\u003e 2021; 12: 628690.\u003c/li\u003e\n\u003cli\u003eKozar I, Margue C, Rothengatter S, Haan C, Kreis S. Many ways to resistance: How melanoma cells evade targeted therapies. \u003cem\u003eBiochim Biophys Acta Rev Cancer\u003c/em\u003e 2019; 1871: 313-322.\u003c/li\u003e\n\u003cli\u003eBetella I, Turbitt WJ, Szul T, Wu B, Martinez A, Katre A\u003cem\u003e et al\u003c/em\u003e. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer. \u003cem\u003eGynecol Oncol\u003c/em\u003e 2020; 157: 765-774.\u003c/li\u003e\n\u003cli\u003eShi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X\u003cem\u003e et al\u003c/em\u003e. DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. \u003cem\u003eCancer Immunol Res\u003c/em\u003e 2022; 10: 1506-1524.\u003c/li\u003e\n\u003cli\u003eHsieh CC, Su YC, Jiang KY, Ito T, Li TW, Kaku-Ito Y\u003cem\u003e et al\u003c/em\u003e. TRPM1 promotes tumor progression in acral melanoma by activating the Ca(2+)/CaMKIIdelta/AKT pathway. \u003cem\u003eJ Adv Res\u003c/em\u003e 2023; 43: 45-57.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"oncogenesis","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"oncsis","sideBox":"Learn more about [Oncogenesis](http://www.nature.com/oncsis/)","snPcode":"41389","submissionUrl":"https://mts-oncsis.nature.com/cgi-bin/main.plex","title":"Oncogenesis","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"DKK1, CKAP4, oxaliplatin resistance, colorectal cancer","lastPublishedDoi":"10.21203/rs.3.rs-4023430/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4023430/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eOxaliplatin is effective against colorectal cancer (CRC), but resistance hampers treatment. We found upregulated Dickkopf-1 (DKK1, a secreted protein) in oxaliplatin-resistant (OR) CRC cell lines and DKK1 levels increased by more than 2-fold in approximately 50% of oxaliplatin-resistant CRC tumors. DKK1 activates AKT via cytoskeleton-associated protein 4 (CKAP4, a DKK1 receptor), modulating oxaliplatin responses \u003cem\u003ein vitro\u003c/em\u003e and \u003cem\u003ein vivo\u003c/em\u003e. The leucine zipper (LZ) domain of CKAP4 and cysteine-rich domain 1 (CRD1) of secreted DKK1 are crucial for their interaction and AKT signaling. By utilizing the LZ protein, we disrupted DKK1 signaling, enhancing oxaliplatin sensitivity in OR CRC cells and xenograft tumors. This suggests that DKK1 as a chemoresistant factor in CRC via AKT activation. Targeting DKK1 with the LZ protein offers a promising therapeutic strategy for oxaliplatin-resistant CRC with high DKK1 levels. This study sheds light on oxaliplatin resistance mechanisms and proposes an innovative intervention for managing this challenge.\u003c/p\u003e","manuscriptTitle":"DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-04-10 05:56:15","doi":"10.21203/rs.3.rs-4023430/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"oncogenesis","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"oncsis","sideBox":"Learn more about [Oncogenesis](http://www.nature.com/oncsis/)","snPcode":"41389","submissionUrl":"https://mts-oncsis.nature.com/cgi-bin/main.plex","title":"Oncogenesis","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"fab25b1e-fd45-4916-9bfe-1be8ccc3c322","owner":[],"postedDate":"April 10th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":29200838,"name":"Biological sciences/Cancer/Cancer therapy/Cancer therapeutic resistance"},{"id":29200839,"name":"Biological sciences/Cancer/Gastrointestinal cancer/Colorectal cancer"}],"tags":[],"updatedAt":"2024-09-28T07:06:14+00:00","versionOfRecord":{"articleIdentity":"rs-4023430","link":"https://doi.org/10.1038/s41389-024-00537-y","journal":{"identity":"oncogenesis","isVorOnly":false,"title":"Oncogenesis"},"publishedOn":"2024-09-27 04:00:00","publishedOnDateReadable":"September 27th, 2024"},"versionCreatedAt":"2024-04-10 05:56:15","video":"","vorDoi":"10.1038/s41389-024-00537-y","vorDoiUrl":"https://doi.org/10.1038/s41389-024-00537-y","workflowStages":[]},"version":"v1","identity":"rs-4023430","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4023430","identity":"rs-4023430","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}